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ABSTRACT 
Antibacterial Hydrogel Coatings Derived from Novel Chemically Responsive Vesicles 
Emily Mobley 
 
In order for a drug, or any material used for the purpose of eliciting a change in an 
organisms’ physical or chemical state, to be effective it must reach the intended target intact 
and for a sustained rate over time. Drug delivery systems encapsulate a drug to protect it 
from degradation, prevent side reactions, increase solubility, improve accumulation rates 
at target sites, and release drugs at a controlled rate. Controlled and sustained release of 
drugs is achieved by degradation of the carrier triggered by breaking dynamic chemical 
bonds caused by changes in the chemical environment such as pH or redox conditions. 
Slow, first order kinetic release of drugs increase therapeutic efficacy while also reducing 
side effects and other cytotoxicity issues. 
Up and coming drug delivery systems include hydrogels and nanocarriers such as 
vesicles. Hydrogel drug delivery systems are unique three-dimensional networks of 
crosslinked hydrophilic polymers that contain anywhere from 50-90 wt% of water. Drugs 
can be loaded via encapsulation during the gelation process or may be covalently bound to 
the polymer backbone before gelation. Amphiphilic molecules or polymers that self-
assemble in aqueous solutions to form supramolecular nanostructures, such as vesicles, can 
encapsulate hydrophilic drugs in the aqueous interior or hydrophobic drugs in the lipophilic 
bilayer membrane.  
This study seeks to embed vesicles into a hydrogel to create a hybrid drug delivery 
system which may be applied as a coating to medical devices to prevent bacterial adhesion 
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and growth, injected directly to a target site, or as an additive for wound dressings. This 
hybrid system mitigates burst release from the hydrogel, as well as stabilizes the vesicles 
to afford a longer shelf life. Vesicles are prepared from a novel supramolecular amphiphile 
composed of thio-alkyl modified 𝛽-cyclodextrin as a macrocyclic host, and an adamantyl-
dithiopropionic acid modified poly(ethylene glycol) as a linear guest. This host-guest 
system forms inclusion complexes that self-assemble to bilayered vesicles, which may 
encapsulate a payload, in aqueous solutions. These vesicles serve as three-dimensional 
multivalent junctions to form a hydrogel, which may encapsulate a second payload, 
through a dynamic disulfide exchange crosslinking reaction. This novel drug delivery 
system will be capable of dual and selective release of two different encapsulated payloads. 
A pH sensitive acid labile bond embedded in the crosslinker will cleave under acidic 
conditions to release the payload enclosed in the hydrogel matrix, while a disulfide bond 
embedded in the supramolecular amphiphile of the free vesicle can be cleaved in the 
presence of naturally occurring antioxidant glutathione, GSH, to release the second 
payload.  
It has been discovered that vesicles efficaciously form, can encapsulate a payload, and 
are stable for several weeks, up to a month. Vesicle stability is examined in the presence 
of both intracellular and extracellular concentrations of GSH, and it is found that vesicles 
are more stable in extracellular concentrations of GSH. Crosslinking of vesicles is 
attempted at several molecular weights of linear thiol terminated poly(ethylene glycol) 
crosslinker, concentrations ratios of crosslinker: vesicle, pHs, and temperatures. It can be 
concluded that the crosslinking density with the linear crosslinker is not high enough to 
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form a hydrogel. Future studies will include 4-arm crosslinkers which are predicted to 
increase the number of crosslinking points and hence the crosslinking density. 
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1. INTRODUCTION 
1.1 Antibacterial Coatings 
 Polymeric coatings are an essential class of materials commonly used for 
substrate protection and/or functionalization, as well as aesthetics and other 
specialty functions. Types of coatings can range from clear to opaque, solvent to 
water to powder based, thermoplastic or thermoset, ambient to radiation cured, 
organic to inorganic, etc., and cover an expansive base of applications such as 
architectural paints and lacquers.1 The complex science behind creating a 
successful coating depends on the material’s end use goal. However, within this 
diverse range of possible end products lies several commonalities as demonstrated 
in Figure 1.1 
 
Figure 1: The process of coating formulation to application and disposal, all of which are 
recurring elements in all coatings’ life cycles 
Raw Materials
Formulation
Storage
ApplicationDrying/Curing
Service Life
Disposal
2 
 
 There are numerous sub-classifications of coatings, among which is 
antibacterial coatings. Antibacterial coatings are becoming increasingly more 
significant across a wide range of industries, particularly within biotechnology and 
medicine.2-7 Of the many challenges this industry faces when creating appropriate 
coating materials, biocompatibility and stability of biomaterials it of utmost 
importance for the material to attain long term use and effectiveness in order to 
protect the substrate and/or provide other functions.2,5,6 Additionally, it is 
imperative that these materials also provide a certain level of antibacterial character 
in order to prevent the proliferation of bacterial infections amongst the fields of 
biotechnology and medicine. Bacterial related infections are currently the 6th 
leading cause of death in the world, with this rate being substantially higher in 
underdeveloped countries.5 These infections are not only threatening from a health 
perspective but also from an economic perspective. Health wise, materials such as 
food processing equipment,  medical devices, and implants are highly susceptible 
to bacterial infection and cause health deficits to the population; whereas 
economically, bacteria colonizing on industrial settings like pipelines, water 
treatment plants, ship hulls, etc. contribute to vast rates of decreased efficiency and 
increased operational costs for these essential industries.6 The root cause of these 
issues can be traced back to bacterial adhesion on surfaces, which is why 
antibacterial coatings have become paramount in research efforts.  
 In terms of treating all types of bacteria-surface related infections, 
antibiotics have been widely used since the discovery of penicillin in 1928, and 
have proven to be highly effective in expelling infections caused by the growth of 
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pathogenic bacteria.8 Public health efforts based on expanding antibacterial 
technology over time have significantly improved the quality of life across the 
globe by suppressing many previously problematic pathogenic bacteria related 
infections. Still, millions of people die annually as a result of these infections 
because of the rise of multi drug resistant microorganisms.2 This is suspected to be 
a direct result of using antibiotics to kill bacteria, and, unfortunately, our ability to 
produce new antibiotics is currently vastly outpaced by these microorganisms’ 
abilities to evolve and give rise to new resistant species.2,5,9 Additionally, antibiotics 
are also subject to poor solubility, cytotoxicity, and environmental toxicity at high 
concentrations when used in isolation, all of which become especially problematic 
for biotechnology, medical, and environmental industries.2,5,6,9 Current methods to 
mitigate these issues involve the development of efficient drug delivery systems 
that reduce the risk of bacterial resistance, as well as regulating concentrations of 
drug agents to avoid both cyto- and environmental toxicity.2,5,6 Additionally, these 
methods also use a variety of different materials aside from traditional antibiotics, 
each of which has its own limitations and efficacy. Among these alternatives, 
include nanoparticles of metal ions, natural extracts such as chitosan and seaweed, 
antimicrobial peptides and enzymes, quaternary ammonium compounds, polymers, 
and superhydrophobic materials.6 Ranking these different materials for coating 
strategies in terms of effectiveness is considered largely impossible because they 
are so dependent on specific clinical applications, which may vary in the need for 
short versus long term use, bactericidal activity, application site, etc.  
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 Nonetheless, each of these surface coating strategies, regardless of material, 
is  largely focused on surface modification to either prevent bacterial adherence, 
kill bacteria on contact with the surface, or release a drug agent to kill the bacteria 
as it approaches the surface, as demonstrated by Figure 2.6.10,11 
 
Figure 2: Three main types of antibacterial coatings being developed to prevent bacteria 
colonizing surfaces and subsequent infections; I. Anti-Adhering Coating- which prevents 
bacterial growth on surfaces, II. Contact Kill Coating- which kills bacteria that come in 
contact with surfaces, III. Antimicrobial Substance Release Coating- which kills bacteria 
that come into contact with surfaces by a stimuli responsive mechanism 
 
Herein, in order to design effective antibacterial coatings within these categories, it 
becomes important to investigate the mechanisms behind bacterial adhesion to 
surfaces. Bacteria-surface interactions trigger certain changes in the expression of 
genes that influence cell morphology and behavior, including those necessary for 
surface mobility and attachment.10 This ability of bacteria to adhere to surfaces is a 
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beneficial evolutionary trait that allows them to grow and proliferate while being 
protected from shear and mechanical damages.10,12 While the phenotypes of this 
evolutionary advantage have been studied and are well known, the underlying 
mechanisms that bacteria use for sensing and responding to surfaces are not.  
 Current research has identified bacterial adherence to occur in two 
consecutive phases; one that occurs rapidly and is easily reversible, and another 
that occurs over several hours and is irreversible.10-13 The first reversible “physical” 
phase is dependent on hydrodynamic and electrostatic interactions between the 
bacteria and the surface, wherein the adhesive force between them increases 
rapidly. The second irreversible “molecular” phase depends on non-covalent 
interactions between the hydrophobic region of the bacterial cell wall with the 
surface, and involves several proteins secreted to the surface by bacteria. While the 
exact molecular mechanisms of these phases are not well understood, we do know 
that they are heavily influenced by the laws of thermodynamics, wherein bacteria 
work to minimize surface energy. Bacterial cells preferentially attach to 
hydrophillic materials (which have high surface energy) when the surface energy 
of the bacterium is larger than that of the liquid surface in which they are suspended, 
but when the surface energy of the bacterium is lower than that of the liquid surface 
in which they are suspended bacterial cells preferentially attach to hydrophobic 
materials (which have low surface energy).10 This is why bacteria are able to adhere 
to such a wide variety of surface types of varying hydrophilicity including glass, 
aluminium, stainless steel, teflon and other fluorinated materials, organic polymers, 
etc. Even with resistant surfaces, bacteria are able to trigger several mophological 
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changes, such as depositing layers of proteins, to make the surface more favorable 
for adhesion.10-13 This creates a large challenge for antibacterial surfaces because it 
requires precise control over surface chemistry, strucutral properties, and the 
environment of a given surface.  
 To make matters worse, once bacteria are able to successfully adhere to a 
surface, they begin to synthesize a hydrated matrix of extracellular polymeric 
substances to form a biofilm, which, once formed, is exponentially more difficult 
to treat as it is highly robust and dynamic in nature.10-13 Biofilm formation is a 
multistep process, as demonstrated in Figure 3, and depends on several factors 
including type of bacteria, type of surface, environmental conditions, and flow 
conditions.11 Because biofilms are so ubiquitous in nature, it may not be possible 
to eliminate them from surfaces, especially because they act as a highly effective 
barrier from any external defenses. Specifically, biofilms act to reduce the net 
negative charge of bacterial cells to enhance the stability of the membrane, and also 
contain many dormant persister cells that are highly tolerant to any antibacterial 
treatment and constantly upregulate specific antibiotic resistant genes within these 
cells.10 In the medical field, bacterial infection and resultant biofilm formation on 
medical devices or implants can begin pre- peri- or post-operatively, and may occur 
over the course of several years, as bacteria are known to be able to maintain a low 
metabolic rate for long periods of time.12 
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Figure 3: Generalized multistep process of biofilm formation; I. Bacteria Attachment to 
Surface, II. Bacteria Mono-film Formation, III. Bacteria Cell-Cell Adhesion and 
Proliferation, IV. Mature Biofilm, V. Biofilm Detachment 
 
In this case, there is a direct competition between host eukaryotic cells and bacterial 
cells on the surface which depends on several factors- physiochemical properties 
of the surface, bacterial concentration and virulence, and eukaryotic cell 
properties.12 In short, there is a molecular race occurring between eukaryotic and 
bacterial cells for integration upon indwelling surfaces of such devices and implants 
which invade surrounding epithelial and mucosal barriers. Common devices that 
are prone to these types of infections include all types of catheters, fracture fixation 
devices, dental implants, prosthetics, vascular grafts, pacemakers, mammary 
implants, mechanical heart valves, and even wound dressings.13 Implanting devices 
innately impairs host defense mechanisms, so infections may rapidly become 
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chronic, wherein the only treatment available is to remove the associated device 
because destroying biofilms involves such high levels of antibacterial agents that it 
would cause cytotoxic effects to the host.3,4,7,13 This is a financial drain for the 
medical and biotechnology industries, as devices and implants are not able to 
achieve their full service life before being replaced, as well as  a health detriment 
to hosts as the infection may still persist after device removal.  
  Combatting these highly evolved genetic advantages of microorganisms is 
no small task and must focus on specific bacterial characteristics such as their 
mechanisms of adaptiveness to different environments. Optimizing thin film 
antibiotic coatings is now largely considered essential, as bulk material properties 
have more or less already been optimized.5 The advantage of thin film coatings is 
that they are able to impart certain characteristics and functionalities to the surface 
without effecting those of the bulk material.1 Relevant surface modifications with 
antibacterial coatings to prevent initial attachment of bacteria and subsequent 
biofilm formation may include altering the chemical composition of surfaces, 
mainly hydrophilicity and charge, as well as roughness and porosity, in order to 
achieve the desired bactericidal effect once applied to a given surface.11-13  All the 
while, we must also take into consideration avoiding any inflammatory responses 
from the host immune system, specificity against cytotoxicity of eukaryotic cells, 
biocompatibility, solubility, long term stability and environmental sustainability of 
materials and processes to make them, antibiotic resistance, over/under dosing, 
etc.2-13 
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 1.1.1 Hydrogel Coatings 
 One such promising material for highly effective thin film antibacterial 
coatings involves the use of polymeric hydrogels. Hydrogels are three-dimensional 
polymer networks often crosslinked by either physical interactions, ie. chain 
entanglements or polymer microstructure interactions, or chemical interactions such 
as intermolecular forces (IMFs) or covalent bonds and are distinct due to their unique 
physical properties.2 One important division to make when discussing hydrogels is 
the difference between hydrogels and gels. Although chemically similar, the two 
materials are physically different in that hydrogels will swell and absorb solvent 
while maintaining their 3D crosslinking network, whereas a gel is already swollen 
to equilibrium when formed and will dissolve in solvent.14 The former is more 
advantageous for coating applications because they are able to continually establish 
equilibrium in response to varying solvent environments.  
 Furthermore, as evident by Figure 4, there are truly an innumerable amount 
of polymer combinations that may form a hydrogel matrix. Therefore, it is important 
to consider specific end use goals when selecting raw materials for any hydrogel 
coating system; in this case, the design of a biocompatible and efficient therapeutic 
delivery system for broad spectrum antibacterial activity.3 Common applications for 
antibacterial hydrogels include a wide range of equipment used in the medical and 
biotechnology industries that suffer from bacterial infections, as previously 
mentioned in section 1.1. 
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Figure 4: Generalized polymer chain entanglements/crosslinking that form thin film 
hydrogels, wherein mesh size may vary from micro- to nanoscale 
 
 Hydrogels inherently  have varying degrees of porosity that allow them to 
absorb water and/or other solvents at hundreds to thousands of times their own 
volume, which lends itself to high swelling capacity, oxygen permeability, 
biocompatibility, and structural diversity.2,6  These traits, among many others, make 
hydrogels highly dynamic and easily customizable materials, and has subsequently 
caused them to be the focus of many research efforts in the field of developing 
antibacterial coatings.  
 In the case of antibacterial coatings in the biotechnology and medical 
industries, hydrophilicity is of the upmost important physical properties, as it allows 
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the material to be biocompatible under physiological conditions.2,3,4 Among 
previously mentioned physical properties, hydrogels also have a high surface area 
to volume ratio, which make them controllable structures than can easily mimic 
natural tissue, which is highly advantageous in terms of compatibility with 
biological systems.6 When coupling this property with an adjustable mesh size, 
hydrogels have also been demonstrated to have the ability to attain controlled and 
prolonged release of encapsulated materials, local administration, and stimuli 
responsivity to certain environmental triggers such as pH, temperature, oxidation-
reduction reactions, and concentrations of particular chemical species.15 This stimuli 
responsiveness can be customized towards a particular end use goal by making 
various chemical and/or physical modifications to the underlying crosslinked 
polymer network structure. In some cases, this responsiveness has allowed hydrogel 
coatings to act as self-healing materials, which is highly desirable in terms of 
attaining long service life and reducing raw materials costs in the long run.16 
1.1.1.1 Hydrogel Coatings Preparation Methods 
 There are a variety of preparation methods for making hydrogel coatings 
with antibacterial activity; each with its own strengths and limitations. These 
methods can be classified into a few categories which are as follows.2 
• Inorganic nanoparticle containing hydrogels 
• Antibacterial agent containing hydrogels 
• Hydrogels with inherent antibacterial capabilities  
 Inorganic nanoparticle containing hydrogels contain nanoparticles such as 
metal ions and metal oxides (ex: silver, copper, gold, silica, zinc oxide, titanium 
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dioxide, and nickel oxide), which have inherent antibacterial character and have 
been demonstrated to maintain broad range antibacterial activity over long periods 
of time while also reducing the likelihood of antibacterial resistant species arising. 
Loading nanoparticles into a hydrogel matrix is a convenient and controllable 
platform for biofunctionalized metal nanoparticles. Although the mechanism of 
action isn’t entirely understood, it is hypothesized that these metal nanoparticles act 
via attaching to the cell wall by electrostatic interactions and subsequently disrupting 
the cell membrane of bacterial cells and/or generating reactive oxygen species to 
induce oxidative stress by free radical formation.6 However, this mechanism for 
antibacterial activity lacks specificity for bacterial cells, and consequently has 
several negative impacts on eukaryotic genes as well. This is because reactive 
oxygen species cause DNA damage, mitosis inhibition, and chromosomal instability 
in healthy eukaryotic cells as well. Hence, when making hydrogel materials 
embedded with metal nanoparticles, it is important to optimize biocompatibility by 
achieving high spatial dispersion of nanoparticles within the hydrogel matrix to 
avoid agglomeration, as well as overall compatibility in an organic environment, so 
as to avoid any damage to healthy cells. This is because agglomeration of 
nanoparticles in a hydrogel matrix can rapidly lead to overdosing and subsequent 
cytotoxicity to the host eukaryotic cells. Similarly, incompatibility in an organic 
environment renders the nanoparticles unstable, and subsequently unsuitable for use 
in biological systems due to the toxicity risk of metal nanoparticles leaching out of 
the hydrogel. Optimization of biocompatibility is most commonly achieved with a 
layer by layer coating method, wherein the layers of the hydrogel coating alternate 
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between containing metal nanoparticles and void of metal nanoparticles.4 This outer 
layer is typically void of metal nanoparticles and acts as a shield to prevent 
cytotoxicity while maintaining long term antibacterial activity. However, this 
method does not entirely prevent damage to eukaryotic cells and therefore is not 
suitable for some applications. 
 The second type of antibacterial hydrogels are antibacterial agent containing 
hydrogels, wherein an “antibacterial agent” can be defined as any material that is 
embedded within the hydrogel matrix for the purpose of eliciting antibacterial 
activity. As previously mentioned in section 1.1 and visualized in Figure 5, 
commonly used antibacterial agents are antibiotics, antibacterial peptides, 
antibacterial enzymes, quaternary ammonium compounds, chitosan, and other 
natural extracts.6 With any of these materials, and especially with conventional 
antibiotics, it is imperative to minimize the development of antibiotic resistant 
bacterial species arising by minimizing the concentration of antibacterial agents to 
that which is able to be effectively bactericidal without inducing extra systemic 
toxicity.  
 The advantage of using conventional antibiotics is that their properties are 
well known and easy to apply in a medical setting, but the drawback is that of the 
antibacterial agents, antibiotics are the most likely to lead to the development of 
antibiotic resistant species. With antibacterial peptides, this is not an issue, as they 
are already present in our immune systems which is advantageous because they are 
biocompatible and do not show any direct toxicity effects on mammalian cells.6 
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Figure 5: Different types of antibacterial agents with examples of structures 
 
These compounds act by using their positive charges to associate with the negatively 
charged bacterial cell wall and disrupt it. However, they are very similar to common 
eukaryotic signaling peptides, so when tethered within a hydrogel matrix they have 
been known to cause undesirable hemolytic effects. Antibacterial enzymes are 
similar to antibacterial peptides in that they are largely considered non-toxic while 
remaining bioactive.6 They are also commonly used in detergents, industrial 
processes, and the food industry and are known to achieve a bactericidal effect in 
hydrogel coatings by preventing bacterial adhesion due to enzymatic degradation of 
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molecules essential for bacterial functionality, or causing direct hydrolysis of the 
bacterial cell wall. The disadvantage here is that retaining enzymatic activity is very 
difficult, as the enzymes tend to become instable when immobilized within a 
hydrogel matrix or on the surface of a coating. With quaternary ammonium 
compounds, their bactericidal effectiveness is dependent on whether the positive 
charge density of the coating is able to exceed the threshold of 1015 N+ cm-2 with an 
alkyl chain length between 4-18.6 This is because the mechanism of action involves 
the quaternary N atom’s attraction to the phospholipid head groups of the cell wall, 
while the hydrophobic tail becomes incorporated into the cell membrane to lyses the 
bacterial cell. These compounds are also, however, limited because they require a 
certain degree of freedom to achieve antibacterial activity. In this case, this 
conformational freedom can be attained by tethering the compound to the surface of 
the hydrogel coating, rather than embedding it which may cause biological 
instability. Finally, chitosan is a naturally derived material with inherent bactericidal 
effects, and is also highly biocompatible and easily modifiable.6 The limitation with 
this material is mainly that the bactericidal activity is low compared to other 
antibacterial agents as it is highly dependent on the degree of chitosan acetylation. 
However, a benefit of using slow release mechanisms from any type of antibacterial 
agent containing hydrogels is that it tends to increase the effectiveness of the 
antibacterial agent itself owing to targeted, minimal usage of materials.6 
 Both inorganic nanoparticle and antibacterial agent containing hydrogels 
generally involve the encapsulation and release of materials from the hydrogel 
matrix, which involves various chemical, physical, and biological triggering 
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mechanisms. A general structure of a hydrogel coating containing an encapsulated 
payload is demonstrated in Figure 6. Additionally, it should be noted that 
encapsulated payloads also vary in loading methods and efficiency, which is highly 
dependent on the compatibility of the specific polymers being used to form the initial 
hydrogel matrix with the encapsulated materials. Most commonly, antibacterial 
hydrogels are made using polyethylene glycol (PEG) or polysaccharides, because of 
their biocompatibility features, and then coupled with any of the bactericidal 
materials previously mentioned. 
 
 
Figure 6: Generalized polymer chain entanglements/crosslinking that form 
thin film hydrogels that are capable of loading various payloads within the 
hydrogel matrix 
 The last type of antibacterial hydrogels are those that have inherent 
antibacterial activity without the incorporation of other materials. Mainly, these 
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hydrogels are those that are comprised of polymers with either non-stimulated or 
potential antibacterial activity. Here, non-stimulated polymers have inherent 
structural components that lend themselves to bactericidal activity, whereas 
potential polymers can be converted to become antibacterial under certain 
conditions. One such common example of this is polymer brush surfaces attached to 
the exterior of a hydrogel. In this case, polymers are used to prevent bacterial 
adhesion by occupying majority of the external surface area to create an osmotically 
driven steric barrier for bacterial adhesion.6 This acts as a passive mechanism to 
avoid bacterial infections on surfaces. In order for this method to be effective in 
terms of antiadhesive properties, the polymers need to be well hydrated, which is 
why covalent or physisorption to the surface of thin film hydrogel coatings is so 
advantageous- because hydrogels are able to hold more water without collapsing 
than a polymer brush surface on its own.6  Polymer brushes on the surfaces of 
hydrogels are, however, limited because they are unable to prevent biofilm 
formation over long periods of time. For this reason, polymer brushes are often 
combined with the loading antibacterial agents to the hydrogel matrix to increase 
bactericidal efficacy over longer periods of time. Similarly, superhydrophobic 
surfaces possess extraordinary antiadhesive properties, and hence are inherently 
highly effective at preventing bacterial adhesion to surfaces.6 However, this method 
is seldom successful in coupling with antibacterial hydrogels because it is inherently 
incompatible with the hydrophilic nature of hydrogels, as well as any biological 
system.  
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 Overall, the most widely utilized methods for preparing hydrogel coatings 
for use in the biotechnology and medical industries involve combining multiple 
types of antibacterial hydrogel coatings; mainly the incorporation of various 
antibacterial agents, which may or may not be coupled with polymer brush surfaces 
or layer by layer coating deposition including inorganic nanoparticles. However, 
current research efforts are still needed to expand upon this technology as many 
more developments are needed to achieve an effective and biocompatible 
antibacterial hydrogel coating material for widespread application. The main 
limitations currently are scaling up production of  materials,  long term stability, and 
efficient use of biocompatible antibacterial agents that have broad spectrum 
bactericidal activity without giving rise to new antibiotic resistant species or other 
undesirable systemic side effects. 
1.1.1.2 Hydrogel Coatings Characterization Methods 
 Antibacterial hydrogel coatings can be characterized for a variety of physical 
properties such as swelling capacity, storage/loss modulus, elasticity, mesh size, 
hydrophilicity, stability, responsivity, encapsulation ability, level of bactericidal 
activity, biocompatibility, and cytotoxicity level. Some common instruments used 
to determine these properties include scanning electron microscopy, transmission 
electron microscopy, atomic force microscopy, x-ray photoelectron spectroscopy, 
dynamic mechanical analysis, and rheology.7,14 
 Because hydrogels can be so structurally diverse depending on the raw 
materials and preparation methods used, it is important to characterize the structure 
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of the hydrogel including porosity, mesh size, and relative uniformity of the 
hydrogel matrix.  
 Surface characterization is often accomplished with a combination of 
microscopy methods. X-ray photoelectron microscopy is a method based on the 
photoelectric effect, which describes what happens when electromagnetic radiation 
hits a material, and measures both the chemical composition and state of the material 
as well as any electronic properties. This is useful for determining the surface 
composition and uniformity of hydrogel coatings.7 To obtain optical images of the 
surface, scanning electron microscopy or transmission electron microscopy are often 
used.14 Scanning electron microscopy acts by emitting beams of electrons to the 
surface which interact with atoms to produce a topographical image of the surface 
composition with a resolution down to a few nanometers. Transmission electron 
microscopy has a much higher resolution due to a smaller de Broglie wavelength of 
electrons transmitted through the sample. These images are useful for determining 
the mesh size and porosity of the hydrogel matrix. Atomic force microscopy is 
another common method that has excellent resolution, up to fractions of a 
nanometer, which is more than a thousand times better than optical diffraction limit. 
This method can produce topographical maps of the surface by scanning with a small 
cantilever tip coupled with laser focusing. Results from these measurements are 
useful for characterizing porosity and roughness of the hydrogel coating surface. 
 Other physical properties are often measured using rheology and dynamic 
mechanical analysis. Because hydrogel coatings can absorb various solvents up to 
about a thousand times their own volume, it is important to characterize the flow 
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behavior of these materials. Rheology relates the relative stress and strain responses 
of the material to various shearing to uncover any viscoelastic properties. This 
measurement is useful because it yields information about for the storage and loss 
modulus of the material, which tells how it will respond to various environmental 
forces once applied to a surface. Similarly, dynamic mechanical analysis 
measurements also characterize viscoelastic properties of the material. This method 
applies a sinusoidal stress to the material and measures the corresponding strain that 
occurs at various temperatures to yield a complex modulus. These measurements are 
especially important when considering antibacterial hydrogels that are to be applied 
in biological systems, as they will be constantly exposed to shear stress from 
surrounding plasma and/or tissue, and must be able to remain stable in response.5 
1.2 Drug Delivery Systems  
 When considering antibacterial hydrogel coatings as a functional material 
for biological applications, it is important to recognize that this material innately 
functions as a drug delivery system. Herein, a “drug” can be defined as any material 
either encapsulated or inherent to the bulk material for the purpose of eliciting a 
change in an organisms’ physical or chemical state once released to the target 
environment.17 Examining the current progress and methods used in upcoming drug 
delivery systems helps us to understand how a hydrogel coating can be customized 
for a variety of biological applications to achieve a therapeutic effect. 
 One of the issues paramount to improving the therapeutic efficacy of drugs 
is that the process of making new drugs is both time consuming and financially 
draining. This is because each new drug molecule made must go through rigorous 
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testing to get approved by the Food and Drug Administration (FDA) for 
commercial use including discovery in vitro, clinical trials in vivo, further 
development and optimization, and regulatory restrictions.17 Herein, the gap from 
“in vitro” to “in vivo” studies is substantial. In vitro studies are typically used as a 
proof of concept phase, but majority of drug candidates that make it past in vitro 
studies will subsequently fail in vivo studies because there is an exponential 
increase is systemic complexity when going from physiological mimetic conditions 
to a true physiological system. Overall, the process of getting a new drug candidate 
approved typically takes an average of a decade and can end up costing over $120 
million dollars.17 Because of this largely impractical protocol for approving newly 
developed drugs, majority of current research efforts have been focused instead on 
creating better drug delivery systems to administer already approved drugs that may 
have issues with absorption and general biocompatibility, site specific activity, 
and/or systemic toxicity issues, etc. on their own.17,18 Perhaps the biggest issue with 
drug delivery is the poor solubility of many pharmaceuticals. In fact, more than 
40% of all currently approved drugs are nearly insoluble in water, which causes the 
drugs to have very poor biocompatibility and distribution since in order for a drug 
is to be properly absorbed, it must be in solution at the target site.19 These features 
subsequently make hydrophobic drugs very problematic to deliver effectively 
because biological systems exist in an aqueous environment, which makes it 
difficult for the insoluble drug to diffuse into cell membranes, so higher 
concentrations of drug are needed to achieve any effect.18 However, this often leads 
to unwanted side effects and/or toxicity issues.18 Hence, some of the goals of new 
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drug delivery technology is to mitigate the aforementioned barriers and deliver 
drugs at a slow and controlled rate over time, with target specific release at the 
appropriate dosage, without eliciting an immunogenic response, systemic toxicity, 
or other harmful side effects.17,18,20  
 With any drug delivery system, there are two primary pathways in which 
drugs may be delivered to the target site- passively, or actively.18 In passive drug 
delivery, the carrier or drug itself will circulate freely until it reaches the desired 
target site, which may be influenced by a variety of external factors such as pH or 
temperature, and then release the drug based on affinity, binding, or stimuli 
responsivity to the target site. In active drug delivery, specific chemical moieties 
are incorporated onto the drug or drug carrier, such as peptides or antibodies, which 
will target a specific site for expression and subsequent drug release. Each of these 
delivery pathways is dependent on a slew of physiochemical and environmental 
factors, which are quite different depending on the drug administration method. 
Many drug administration methods are demonstrated by Figure 7, wherein each 
method has its own pros and cons. Generally, oral administration is preferred 
whenever possible because it has the highest levels of patient cooperativity and is 
easy to follow. Transdermal, topical, and injection methods are also generally 
preferable because they are relatively simple to administer and bypass the first pass 
effect, wherein the concentration of a drug taken orally is greatly reduced by first 
pass metabolism before it reaches systemic circulation.19,2121 This allows lower 
concentrations of drugs to be administered, which is advantageous because less 
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drug is needed to achieve the same effect. However, it is impractical to rank these 
drug administration methods, as they are each used for specific purposes.  
 
 Figure 7: Routes of drug administration for all types of pharmaceuticals 
 
 Regardless of administration method, for drugs to be delivered and achieve 
the desired therapeutic effect, they must have adequate bioavailability. This means 
that the drug must have a substantial fraction of the initial dose that reaches 
systemic circulation and eventually its target site. Bioavailability is influenced by 
aqueous solubility levels, drug permeability to the target site, dissolution rate, first 
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pass metabolism, pre-systemic metabolism, and susceptibility to efflux 
mechanisms that remove solutes from cells.19  Additionally, it is important to 
maximize the therapeutic index of drugs. This parameter compares the amount of 
drug that elicits a therapeutic effect to that which causes toxicity.22 Therefore, the 
higher the therapeutic index, the safer the drug. Although increasing bioavailability 
and therapeutic indices of drugs are the main overarching goals of new drug 
delivery technology, there are a variety of different systems emerging which 
attempt to mitigate a range of issues related to drug delivery. 
 1.2.1 Types of Drug Delivery Systems  
 One aspect that majority of new drug delivery systems have in common is 
that they implement some sort of external carrier that serves to both protect the drug 
from the surrounding environment, and efficaciously deliver it to its target site.20,22 
Previous research in the field has established that macromolecular carriers and/or 
conjugates for drug molecules are highly effective tools for delivering drugs in a 
safe and controlled manner to their target sites in vivo. The continuing evolution of 
these carrier systems offers several desirable benefits to improve drug delivery such 
as the simplification of drug administration schemes, reducing toxicity levels of 
drugs in circulation, and overall improving therapeutic indices and disease 
outcomes.20 There are several requirements that must be met in order for a carrier 
to be successful.20 First and foremost, the carrier must be able to encapsulate a 
sufficient amount of hydrophobic and/or hydrophilic drug and remain in circulation 
in a physiological medium with tunable leakage. Additionally, the carrier must be 
able to target, accumulate, and distribute the drug at the desired site, as well as 
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increase bioavailability and biocompatibility of the drug. The carrier may 
accomplish this by solubilizing the drug, minimizing drug interactions with non-
target cells, such as endocytosis or absorption, and minimizing elimination or 
degradation of the drug before it reaches its desired target site. Finally, the carrier 
must not illicit any immunogenic responses from the host immune system, be safe 
at all stages of drug delivery (ie. before, during, and after drug release), and must 
have a cost-effective synthetic pathway with ease of scale up. 
  
Figure 8: The most significant nanoscale drug carriers explored in current research; 
micelles, telo-dendrimers, inorganic nanoparticles, hydrogels, linear polymers, 
quantum dots, dendrimers, and liposomes 
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 Specific carrier targeting mechanisms will be reviewed in a later section 
(ie.1.2.2), and here we will take a closer look at the different types of carriers 
currently in development, as demonstrated in Figure 8. Particularly, we will be 
looking at nanoscale drug carriers, as they have been shown to have significantly 
better uptake by cells than larger particles.  
 As the archetype of nanoscale drug delivery platforms, liposomes were the 
first to be approved for clinical use in 1995 (Doxil ®, delivers doxorubicin for the 
treatment of various cancers) and have since gained in popularity and technological 
developments.23 Liposomes are formed by the self-assembly of amphiphiles, and 
consist of a bilayer membrane that is similar to that of biological cells, which makes 
liposomes suitable for mimicking fundamental cellular functions such as motility 
and shape changes in response to the extracellular environment.20,23 This biological 
mimic behavior allows liposomes to go largely undetected by the host immune 
system as a foreign body, which is highly advantageous for a drug carrier as it 
prevents immunogenic responses. However, most liposomes in development are 
phospholipid based and tend to have poor stability and rapid clearance due to strong 
interactions with circulating proteins in blood plasma.20 For this reason, it is 
common to use poly(ethylene glycol) (PEG) and its derivatives, as either part of the 
liposome itself or grafted to the exterior of the membrane in some way, to further 
impart stealth properties on the liposomal carriers.24 This is because PEG is soluble 
in both aqueous and organic media, is non-ionic, and is subsequently known to 
function as an inert polymer to improve circulation time and biocompatibility of 
liposomal drug carriers.20,23,24 
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Figure 9: A closer look at general the structure of liposomes 
 
 
 Taking a closer look at the general structure of liposomes in Figure 9, we 
see multiple sites for drug encapsulation (ie. within the lipophilic intramembrane, 
or within the hydrophilic interior cavity). This is highly advantageous because it 
allows liposomes to encapsulate both hydrophobic and hydrophilic drug molecules, 
which also makes for better cell penetration for hydrophilic drugs and improved 
solubility for hydrophobic drugs.20 Another feature of these types of carriers is that 
the physiochemical properties are easily customizable for a variety of target sites 
and improving biodistribution, circulation times, loading capacity, etc.20,23 Being 
such, there are several different classifications of liposomes. Liposomes may be 
classified according to lamellarity (ie. uni, bi, or multi), size (ie. small <100nm, 
intermediate 100-250nm, large >250nm, or giant >1𝜇m), surface charge (ie. 
anionic, nonionic, or cationic), etc.20 Typically, the type of preparation method will 
have a large impact on these factors. For example, using the common thin film 
hydration method on its own usually results in oligolamellar and polydisperse 
liposomes, whereas coupling this method with extrusion as a purification method 
will exclude larger aggregates and results in a more monodisperse, unilamellar 
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liposome solution. Generally, monodisperse and unilamaller are preferred because 
they tend to behave more uniformly and predictably, which is useful for creating 
statistical models to predict how they will interact with eukaryotic cells.20 
Furthermore, there have been several sub-classifications of liposomes for 
improving various features such as transferosomes for improving elasticity, 
ethosomes for improving skin cell penetration, pharmacosomes for improving the 
delivery of poorly soluble drugs, niosomes, virosomes, nebulized, stimuli 
responsive, and specific cell targeted liposomes.21,23 However, majority of these 
modifications have largely been unsuccessful thus far due to a variety of factors 
ranging from instability to difficulties with industrial production and storage, apart 
from stimuli responsive and specific cell targeted liposomes, which will be further 
discussed in section 1.2.2.  
 Another type of drug nanocarrier like liposomes are micelles. These are also 
formed from the self-assembly of amphiphiles and hence also have both 
hydrophobic and hydrophilic moieties capable of encapsulating both hydrophobic 
and hydrophilic drugs.25 They are much smaller than liposomes, on the order of 
approximately 1-10nm, which makes for improved cell penetration. However, these 
carriers aren’t as successful as liposomes because they are much less stable in 
physiological media and hence tend to suffer from early drug release and 
degradation.20  
 Still, there are other polymeric nanocarriers such as dendrimers, telo-
dendrimers, linear polymers, and hydrogels. Linear polymers are the most 
simplistic model, and yet possess innumerable possibilities for chemical and 
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physical modifications. These materials can be either natural or synthetic, and 
typically function by forming either a drug-polymer conjugate colloid suspension 
or the aforementioned nanostructures (ie. liposomes or micelles).20 Dendrimers, on 
the other hand, are highly branched polymers made from either convergent or 
divergent reaction schemes that generate several generations of branching. These 
materials are globular in shape, well defined, monodisperse, and multivalent 
structures with large surface area functionality capable of encapsulating a variety 
of drug molecules at a high loading capacity for controlled delivery and enhanced 
cell permeation which results in overall better distribution physiologically.20,21  
Telo-dendrimers combine a linear polymer chain with a dendritic segment to 
enhance the self-assembly and mobility properties of the linear polymer chain, with 
the uniformity and multivalence of dendrimers.20 In theory, this system should 
function ideally for controlled encapsulation and release of drug molecules, but 
these materials are still in the very early stages of development so there are not 
many successful examples to speak of yet.24 Conversely, polymeric hydrogels have 
been widely explored for applications as nanocarriers in drug delivery technology. 
As previously mentioned in section 1.1.1, hydrogels have numerous advantageous 
and easily tunable physical, chemical, and mechanical properties which make them 
ideal for interacting with biological systems. In fact, hydrogels are the closest 
mimic to biological tissues of any of the current nanoscale drug delivery platforms. 
This is because of their high water content and soft rubbery texture, which makes 
for very low interfacial tension with surrounding tissues and subsequently a low 
tendency to absorb proteins from blood and other bodily fluids.14,26,27 Possibly the 
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most unique feature of hydrogels that make them ideal for drug delivery is that they 
have been demonstrated to have self-regulating capabilities. Herein, the hydrogel 
matrix has a seemingly elastic memory which allows it to respond to changing 
metabolic states in the body by swelling, altering network structure, permeability, 
and/or mechanical strength, and then alter their release profile accordingly before 
returning to their original state.14 Hydrogels are also ideal for implantable localized 
drug delivery, which maximizes therapeutic efficacy and minimizes side effects 
when compared to systemic approaches.27 However, like other nanocarriers, 
hydrogels have a few drawbacks which are limiting their clinical viability such as 
a limited ability to load hydrophobic drugs, and burst release of drug molecules.26,27  
 Alternative to polymeric nanocarriers, there are also quantum dots and 
inorganic nanoparticles. These systems deliver drugs by coupling drug-ligand 
conjugates to the surface, and accumulate successively at the target site by an 
external magnetic field, but it is important that they are combined with another 
delivery system, as they suffer from chronic uncontrolled release and clearance on 
their own.21 
 1.2.2 Stimuli Responsive Delivery Mechanisms 
 Considering the issues with current nanocarriers as drug delivery systems, 
mainly burst release of drug molecules at sites other than the target site, rapid 
physiological clearance, and general instability, it becomes clear that these 
nanocarriers could benefit from stimuli responsive delivery mechanisms. Smart 
materials, as they are often termed, are of increasing interest for a variety of 
industries, including biotechnology and medicine, because they are able to receive, 
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transmit, or process a stimulus and respond by producing a useful effect.14,26,28,29 
There have been many research efforts made to try to understand stimuli responsive 
mechanisms in biological systems so that we may create effective mimics of our 
own. Polymer based systems (ie. liposomes, micelles, linear polymers, dendrimers, 
telo-dendrimers, and hydrogels) are exceptional materials for this purpose as they 
are able to be made at large scales with a wide range of functionalities and post-
synthetic modifications, and can be processed into a variety of different forms.24,28  
Figure 10: Various potential stimuli and responses for nanocarrier drug delivery 
systems 
 Several potential stimulus and responses are demonstrated by Figure 10, but 
not all of these are viable for physiological applications because once the 
nanocarrier enters the body, it is limited in the amount of stimuli present. Those 
that are of the most interest for these systems are pH and temperature, because 
physiological systems consist of many different organs, organelles and other 
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compartments that vary in both pH and temperature.28,.29 Specific organ and cell 
targeting has been a dream of pharmaceutical companies ever since the industry 
began, because when a drug is targeted to a specific site either by affinity, charge, 
etc. it eliminates potentially harmful side effects and toxicity to the system as a 
whole. Coupling this targeting with stimuli responsive controlled release 
mechanisms furthers this beneficial effect and makes for even more specific drug 
delivery pathways.  
  For example, cancer tissue and chronic wounds are known to have a lower 
pH, which makes pH sensitive linkages a target that can be used to elicit a response 
(ie. release of the drug molecule) from a nanocarrier. Incorporating acid sensitive 
moieties, such as acid labile bonds, on any of the previously mentioned polymeric 
materials is useful for triggering controlled release of a drug from nanocarriers at 
an acidic target site as the change in pH will elicit a conformational and/or chemical 
change in the nanocarrier which causes it to release the active drug.29 As another 
example, glutathione, a natural antioxidant found in higher concentrations 
intracellularly than extracellularly, is also a suitable trigger which elicits a dynamic 
covalent reaction between its thiol group and any disulfide modified polymer on a  
nanocarrier to produce a dynamic covalent reaction which could cause the 
nanocarrier drug release at a sustained and controlled rate.29 Overall, these are just 
a few examples, as there are a wide variety of potential stimuli that can be installed 
onto nanocarriers, and there has been an abundance of research into this area that 
has shown various methods to be successful in improving circulation times, 
stability, and controlled and targeted delivery mechanisms for drug molecules.26-29 
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 Furthermore, researchers have also been able to combine different types of 
nanocarriers together with stimuli responsive moieties installed, which highlights 
how truly innumerable the possibilities are for customizing the properties of 
nanocarriers for drug delivery.28  
1.3 Supramolecular Chemistry 
 Another key factor amongst biological systems- supramolecular chemistry, 
although somewhat recently a discrete field of interest for biologists, chemists, and 
physicists, has been a fundamental aspect of life since its origin. This is because 
supramolecular chemistry is the ubiquitous factor that controls many biological 
functions such as signal transduction, membrane transport, enzymatic reactions, 
binding antibodies to macrophages, cell-cell recognition, protein folding, etc.30-34. 
Contrary to covalent bond formation to form molecules, supramolecular chemistry 
takes advantage of non-covalent interactions to form molecules. Although non-
covalent interactions are individually weak compared to covalent bonds, taken 
collectively they are quite powerful.31 These non-covalent interactions include a 
variety of intermolecular forces such as hydrogen bonding, dipole-dipole, van der 
waals, electrostatic attraction, 𝜋-	𝜋 stacking, metal coordination, charge transfer, 
etc.31,35-38 Nature provides us with one of the most prolific examples of 
supramolecular chemistry in action- the deoxyribonucleic acid (DNA) double helix 
structure. These polymeric strands are held together primarily through  𝜋-	𝜋 
stacking and hydrogen bonding and are able to store, receive, and process vast 
amounts of information all while being both responsive and adaptive to the external 
environment.31,32 Structures, such as DNA, that are held together through non-
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covalent interactions are commonly called supramolecules. Supramolecules are 
complex structures made up of many smaller building blocks held together very 
precisely by non-covalent interactions.31 Studying biological building blocks such 
as nucleic acids for DNA, proteins for protein folding, and lipids for cell 
membranes that each create sophisticated hierarchical structures that are held 
together by non-covalent interactions helps researchers understand how they can 
mimic this molecular recognition behavior synthetically. The first synthetic 
supramolecules on record were crown ethers, for which the Nobel Prize in 
Chemistry was awarded in 1987 to Lehn, Pederson, and Cram for their design and 
development of cryptans, crown ethers, and cavitands, respectively.30,31 These 
complex structures have many interactive properties and are easily customizable 
for a variety of applications such as sensors, luminescence, gels, biological and cell 
imaging probes, liquid crystals, etc.31 The possibilities are truly endless with these 
dynamic materials, which makes them very attractive for research and development 
across many fields of study. 
 Over the years since their synthetic journey began, supramolecules have 
evolved to even more complex and larger architectures such as macromolecules, 
multimetallic helicates, rotaxanes, coordination polymers, etc.31 Continuously 
evolving and inspired by several biological systems and processes, supramolecular 
chemistry primarily relies on the programmed self-organization of its building 
blocks. This self-organization has been termed self-assembly, wherein the building 
blocks spontaneously yet controllably organize themselves into complex and 
sophisticated architectures, driven by non-covalent interactions.32 This type of non-
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covalent synthesis is superior to traditional covalent synthesis in that it is simplified, 
the bonds form spontaneously without any harsh conditions or chemical reagents, 
are reversible under thermodynamic equilibrium, conditions, and do not produce 
any undesired side products.30,35  The bottom up assembly style allows for highly 
specific control over properties of the resultant complex structure because it begins 
with the simplest building blocks and as they bind together increase in complexity 
which results in highly homogenous chemical assemblies with less defects and 
better short- and long-range ordering.30 For example, stereo-control (ie. controlling 
which stereoisomers are formed by a reaction) over covalent synthesis is difficult 
but possible, whereas with non-covalent synthesis it is exponentially more difficult 
in theory because bonds of the individual building blocks are kinetically labile and 
are continuously breaking and reforming. However, in practice, stereo-control with 
self-assembly is not an issue because of the amplification of chirality, wherein the 
achiral building blocks seem to follow the chiral building blocks in their self-
assembly pattern regardless of the relevant concentrations.30 Overall, self-assembly 
of supramolecules requires precise control at the molecular level, which then 
influences the macroscopic level and bulk material properties. 
 1.3.1 Amphiphiles as Building Blocks for Self-Assembly 
 Perhaps the most powerful self-assembly building blocks are amphiphiles, 
which are also called surfactants (ie. surface active agents) interchangeably. 
Amphiphiles are characteristic in that they contain both a hydrophobic and a 
hydrophilic moiety, which may be linked together covalently or non-
covalently.25,34-38 When they are linked non-covalently the amphiphile is then 
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referred to as a supra-amphiphile. Regardless of how bonds are formed, there are a 
variety of different types of amphiphiles which are classified based on structural 
components. Topologies can range from any combination of hydrophilic “head” 
groups and hydrophobic “tail” groups. For example, one hydrophilic head with one 
hydrophobic tail, two tails one head, etc. Two unique topologies are termed 
bolaform, in which two hydrophilic groups are covalently linked to a single 
hydrophobic chain, and gemini, in which two different amphiphiles are linked at 
their charged head groups.35  
 One property that makes these molecules particularly unique and powerful 
tools for self-assembly and supramolecular chemistry is that when they are 
suspended in water, the hydrophilic moiety prefers the aqueous phase, while the 
hydrophobic moiety prefers an organic phase. Depending on the particular 
amphiphile topology, self-assembly behaviors and subsequent physical properties 
will differ because a different structure means different interactions in solution 
which leads to different aggregations. Typically, amphiphiles will first form a 
monolayer at air-water interfaces with the hydrophobic moiety facing the air and 
the hydrophilic moiety facing the aqueous solution, but when the concentration of 
amphiphile in solution is high enough they are driven to self-assemble based on the 
repelling and coordinating forces between the hydrophobic and hydrophilic 
moieties and the surrounding environment, as visualized in Figure 11.36 
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Figure 11: Amphiphiles containing a hydrophobic and hydrophilic moiety may self-
assemble into a variety of nanostructures in aqueous media including but not limited 
to a) Micelle b) Bilayer c) Vesicle 
This phenomenon is driven by the hydrophobic effect, and will occur at or above 
the critical micelle concentration (CMC) (ie. the concentration at which 
amphiphiles form micelles in solution). Further increasing the concentration of 
amphiphile beyond this point will result in nanostructures of increasing complexity, 
such as bilayers and vesicles.39  
 Herein, the hydrophobic effect can be defined as the tendency for 
hydrophobic segments of molecules to exclude themselves from the surrounding 
aqueous media by forming aggregates in solution where the hydrophobic segments 
of amphiphiles interact with each other, while the hydrophilic segments interact 
with the surrounding aqueous environment.40 The hydrophobic effect is a 
thermodynamic phenomenon which is effected by both enthalpy and entropy, and 
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is overall thermodynamically favorable and hence spontaneous. Although it may 
seem counterintuitive at first, the hydrophobic effect is primarily driven by entropy, 
except at high temperatures where enthalpy is the driving force.40-43 This is because 
of the relationship between the free energy required for hydrophobic hydration and 
the strength of the water mediated attraction between pairs of solute molecules. 
When a hydrophobic molecule is dissolved in water, the water molecules form 
highly ordered networks around the molecule. In order to minimize the surface area 
exposed to the aqueous environment, the hydrophobic molecules will aggregate 
with each other to exclude water and the water molecules involved in the highly 
order network are then free and the entropy of the water increases. When compared 
to the entropy loss of hydrophobic moieties creating ordered structures in solution, 
this gain in entropy from freeing water molecules is orders of magnitude higher.42 
Therefore, the entropy loss of forming ordered structures is significantly less in 
magnitude than the entropy gained from the freeing of water molecules.40-43 Hence, 
forming ordered nanostructures in aqueous environments is actually highly 
entropically favorable. The hydrophobic effect is central to the self-assembly of 
amphiphiles into highly ordered nanostructures, in which the function of the whole 
is much greater than the sum of its parts.31   
 1.3.2 Inclusion Complexes with a Host-Guest Based System  
 One particularly unique class of supramolecular amphiphile non-covalent 
assembly is driven by host-guest interactions, which refer to the forming of a 
supramolecular amphiphile in which one component includes within the other, as 
demonstrated by Figure 12. 
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Figure 12: Inclusion complex formation reaction involves the combination of a 
compatible host and guest molecule, which will then self-assemble 
Typically, a small organic molecule will include within the hydrophobic cavity of 
a macrocyclic host. The host and guest molecule can be functionalized with one 
component possessing hydrophobic tail and the other functionalized with 
hydrophilic moieties. Then, instead of covalently linking the hydrophilic and 
hydrophobic portions of the molecules, a supramolecular amphiphile will 
spontaneously self-assemble in aqueous solutions. This type of host- guest 
chemistry is driven by the hydrophobic effect and favorable non-covalent 
interactions. The combination of these forces can form a stable complex, which 
may be comparable in strength to a covalent bond.35, 44 This non-covalent synthesis 
forms an inclusion complex which, dependent on the degree of amphiphilicity, will 
self-assemble into a variety of nanostructures in aqueous media. Herein, the 
inclusion complex is typically formed by the evaporation of solvent to create a thin 
film, and subsequent hydration of this film will give rise to self-assembly.39 The 
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binding ability of the host-guest can be mainly attributed to the hydrophobic 
interactions and the complementary character of both size and shape in the 
molecular components.31, 44  Therefore, host and guest combinations will form 
inclusion complexes based on binding affinity with stronger affinity resulting in 
more robust inclusion complexes and subsequent supramolecular architectures.  
 One of the principle advantages of supramolecular assemblies, and 
particularly inclusion complexes, is that they are dynamic, easily reversible, and 
can be customized to be responsive to various environmental and chemical stimuli 
such as pH, light, temperature, voltage, etc.35, 44 Macrocyclic hosts are especially 
attractive for this purpose because they offer a cavity with multiple recognition sites 
for inclusion of a guest molecule, and can be tailored to promote self-assembly into 
well-defined architectures by the addition of hydrophilic and/or hydrophobic chains 
on either side of the macrocyclic framework.34 
1.3.2.1 Cyclodextrin Hosts 
 There are several different classes of macrocyclic hosts such as calixarenes, 
crown ethers, and cucurbiturils, but by far the most widely used hosts are 
cyclodextrin (CD) derivatives.44 These macrocyclic oligosaccharides are composed 
of several D-glucose rings with 𝛼-1,4 linkages, where 𝛼CD has six repeat units, 𝛽CD has seven, and 𝛾CD has eight.34, 44, 45 The truncated toroidal cone shape of 
these molecules possess a hollow, tapered cavity of 0.79 nm in depth, where the top 
and bottom diameters are influenced by the number of repeat units, as demonstrated 
by Figure 13.45  
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Figure 13: A closer look at the structure of cyclodextrin derivatives a) 𝛼CD, b) 𝛽CD, and c) 𝛾CD where the wider side of the cavity measures 0.57 nm, 0.78 nm, 
and 0.96 nm, respectively, while the depth remains constant at 0.79 nm. Positions 
2, 3, and 6 are indicated accordingly 
This hollow interior cavity is hydrophobic, which is ideal for encapsulating guest 
molecules of the appropriate size and shape for inclusion complexation, while the 
exterior is hydrophilic, which is ideal for interacting with surrounding aqueous 
media.44-46 Here, the CD itself may be amphiphilic based on synthetic 
modifications, or the inclusion complex may create a supramolecular amphiphile 
through non-covalent interactions. Inclusion complexation with a variety of guest 
molecules and synthetic modifications of CDs have been extensively studied, and 
perhaps the most powerful inclusion capacity is 𝛽CD with adamantane, with a 
binding association constant of around 1x105 M-1 in water.34, 45, 46 It is important to 
note that inclusion complexation innately alters the amphiphilicity of the CD, which 
subsequently alters both the chemical and physical properties of self-assembled 
bulk materials to make for advantageous easily customizable systems.  
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 Among the principle benefits of using CDs and their derivatives as hosts is 
their excellent biocompatibility, unique inclusion complex formation capabilities, 
powerful functionalization capacity with ease of synthetic modification, stability 
across a wide range of pH (ie. 1-11), and negligible toxicity.34, 44-46 These properties 
also make CDs ideal candidates for developing new drug delivery systems and 
other materials used in biological systems. In fact, CDs have been utilized 
extensively in this field with more than 30 CD based pharmaceuticals currently 
marketed, and many others undergoing phase I/II trials.45 These supramolecular 
assemblies have been shown to increase drug solubility and stability, enhance drug 
absorption and permeability, control drug release profiles, decreasing toxicity, 
etc.45 Because of the abundant hydroxyl groups on native CDs, chemical 
modifications offer infinite opportunities to further improve upon the 
aforementioned physiochemical properties and molecular recognition abilities for 
specific applications. It is common to install charged groups, and either hydrophilic 
or hydrophobic moieties at position(s) 2, 3, and/or 6 to achieve specific 
functionality in bulk materials.44-46 Overall these synthetic modifications give rise 
to three main classes of CDs- amphiphilic, hydrophobic, and polymer containing; 
all of which have multiple recognition sites for binding molecules of varying 
hydrophobicity/hydrophilicity. These hierarchical self-assemblies are especially 
interesting when combined with polymers, since their unique characteristics depend 
on individual molecules’ properties and polymers are known to possess extremely 
useful properties on their own, which can be amplified using supramolecular 
assemblies with CDs.45, 46  
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 1.3.3 Self-Assembly Features 
 Specifics of the numerous interactions that govern self-assembly of 
amphiphiles is, in part, related to the amphiphilicity of individual molecules. The 
degree of amphiphilicity is often termed the hydrophilic lipophilic balance, or 
HLB.47 The HLB describes the size of the hydrophilic moiety relative to that of the 
hydrophobic. This determines the mean radii of curvature of the hydrophobic-
hydrophilic interface, which relates to the individual components’ radii of curvature 
and the relevant Gaussian curvature to give the overall packing parameter that 
determines what kind of nanostructures may form.47 For example, in order for an 
amphiphile to form bilayers and/or bilayered vesicles in solution the product of the 
hydrophobic-hydrophilic interfacial area and the alkyl chain length must approach 
uniformity with the hydrophobic volume, which yields a packing parameter of 1.47  
However, the HLB of amphiphiles not only determines what type of inclusion 
complex and supramolecular architecture they may self-assemble into. Chemical 
linkages may provide a triggered degradation mechanism for nanostructures which 
is highly advantageous for developing stimuli responsive materials.44 
 Besides relevant size and shape of amphiphiles, thermodynamics also 
govern the self-assembly of amphiphiles, as previously discussed in part in section 
1.3.1, as these molecules aim to lower interfacial energy.40-43, 47, 48 Additionally, 
concentration of amphiphile in solution also plays a part.49 Typically, the first 
aggregates observed in solution are monolayers, and then some form of micelles. 
Further increasing the concentration results in several more complex aggregates, 
depending on the HLB and shape of the amphiphile, as demonstrated by Figure 14. 
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Figure 14: The relationship between amphiphile concentration and temperature gives 
rise to a variety of nanostructures of self-assembled supramolecular complexes 
 
1.3.3.1 Vesicles  
 One particular aggregate omitted from Figure 13 is vesicles. Liposomes, 
previously discussed in section 1.2.1, although sometimes termed interchangeably 
with vesicles, are not the same on a molecular level. Liposomes refer to vesicles 
formed from lipids, most commonly, phospholipids. Therefore, all liposomes are a 
type of vesicle, specifically self-assembled from lipids, while vesicles may be self-
assembled from all types of amphiphiles, including small molecules and polymers, 
that exhibit the appropriate size, shape, HLB, etc. for bilayer, and subsequent 
vesicle formation.47 Here, the lamellar bilayer observed in Figure 13 will begin to 
fold upon itself to form a spherical vesicle in a two-step process.  
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 Although liposomes and vesicles possess the same overall macromolecular 
shape that forms an aqueous interior separated from the bulk solution by one or 
more bilayers of self-assembled amphiphiles, their physical and chemical 
properties can vary quite dramatically.48 For example, their abilities to encapsulate 
and release a payload in a sustained and controlled manner at a designated target 
site varies based on the particular amphiphilic building blocks’ strength of non-
covalent interactions and thickness of the bilayer membrane.47, 48 Because the 
membrane is a semi-permeable barrier, both nanostructures tend to suffer from 
premature leakage of either hydrophobic or hydrophilic encapsulated payloads, and 
yet vesicles tend to suffer less so than liposomes owing to their superior adaptability 
to external environments.47-49 This is because phospholipids tend to hydrolyze 
easily and so their liposomes have shorter shelf lives in aqueous solutions. In 
general, compared to liposomes, vesicles tend to show superior dynamic stability 
and mechanical strength/flexibility, and also offer much more numerous 
opportunities for customizing physiochemical properties such as stimuli 
responsiveness, and self-healing.47, 49 Particularly, polymeric vesicles demonstrate 
excellent capability here, owing to the highly dynamic nature of polymers.  
 Characterization of vesicles typically includes measurements of 
hydrodynamic radius, encapsulation ability, stability, stimuli responsivity, 
controlled release kinetics, and overall shape and surface functionality.49 
Hydrodynamic radius is most easily measured  using dynamic light scattering, 
wherein the size distribution of small aggregates suspended in solution are analyzed 
as an intensity/photon autocorrelation function to account for fluctuations in 
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aggregate distribution due to Brownian motion. Encapsulation ability can be probed 
with a variety of methods which may include using a fluorescent small molecule as 
a proof of concept, or a sample drug molecule for more specific measurements. 
Herein, in order to determine whether vesicles have encapsulated a payload, they 
must be destroyed, and the concentration of the encapsulated payload is then 
measured. Stability measurements can be taken over time using dynamic light 
scattering. The typical hydrodynamic radius of vesicles is on the order of 50-100 
nm. When vesicles degrade, they may form micelles in solution which typically 
have hydrodynamic radii of around 1-10 nm, or they may form even larger 
aggregates with radii >>100 nm. Stimuli responsivity and controlled release 
kinetics are often measured collectively, as it is of interest to see the controlled 
release profile of vesicles in response to external stimuli. Herein, a particular 
stimulus is applied and released concentration of encapsulated payload can be 
measured using a variety of techniques including dialysis, UV spectroscopy, etc. 
Finally, to get a morphological view of vesicles, scanning electron microscopy, x-
ray photoelectron spectroscopy, transmission electron spectroscopy, etc. are used, 
as previously discussed in section 1.1.1.3. 
1.4 Dynamic Covalent Chemistry 
 While supramolecular chemistry has revolutionized the bottom-up 
assembly of functional nanoscale materials with the dynamic reversibility of self-
assembly that takes advantage of non-covalent interactions, dynamic covalent 
chemistry exploits reversible covalent bonds to generate covalent systems that, like 
supramolecular systems, can adapt, respond, and degrade in a controlled manner.50-
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51 Both allow the modification of molecular components; where supramolecular 
chemistry provides molecular recognition and directed self-assembly in a 
controlled manner beyond molecules, dynamic covalent chemistry imparts the 
dynamic feature on the molecular level by breaking and forming covalent bonds 
within molecules that may be used as building blocks in supramolecular self-
assembly.52  Dynamic covalent chemistry has primarily been explored in the fields 
of materials science, biotechnology, and medicine to create functional responsive 
sensors, adaptive membranes, drug delivery systems, etc.50 By combining the 
multivalent error correction and proofreading mechanisms of supramolecular 
chemistry with the robustness and innate strength of covalent bond formation 
dynamic covalent chemistry has evolved to offer potential improvement upon the 
stimuli responsivity of supramolecular architectures.51 The key feature of these 
reactions is the thermodynamically controlled product distribution at equilibrium.  
Herein, the exchange of molecular components at equilibrium achieves a 
thermodynamic minima of the system that is adaptable to the surrounding 
environment, in which the most stable product will predominate.51, 52 
 Typically, reversible covalent reactions are undesirable and tedious 
compared to supramolecular reactions because the breaking and forming of 
covalent bonds has much slower kinetics, may require the use of a catalyst, and 
result in low yields and low conversation rates.50, 51 Therefore, dynamic covalent 
reactions with fast kinetics under mild conditions are preferable. In general, there 
are a few requirements for dynamic covalent reactions to be useful for modifying 
nanostructures on the molecular level.52, 53 First, the lifetime of the reversible 
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covalent bond should be on the order of 1 ms < 𝜏 < 1 min, where 𝜏  is the bond 
lifetime, to ensure that they are stable enough to bond molecular structures and yet 
have dynamic behavior. The reaction must also be able to proceed under mild 
reaction conditions, and the exchange mechanism should have a functional trigger 
(ie. temperature, pH, light, removal of catalyst, redox), much like an on/off switch, 
to isolate particular products.  
 Although dynamic covalent chemistry is a relatively new and insufficiently 
explored field as of yet, there are numerous dynamic covalent reactions that have 
been discovered and more or less optimized.50-52 Mostly, these reactions proceed as 
exchange types, where one component is exchanged for another and the products 
will have the same type of bonding as the reactants, or formation types, where new 
types of bonds are formed.52 So far, dynamic covalent bonds that have been heavily 
researched include C-C, C-O, C-N, C-S, B-O, and S-S (ie. carbon to carbon, carbon 
to oxygen, carbon to nitrogen, carbon to sulfur, boron to oxygen, and sulfur to 
sulfur, respectively). These dynamic covalent bonds and their subsequent reaction 
possibilities are summarized in Table 1.50-52 
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Table 1: Types of dynamic covalent chemistry reactions according to bond type 
Type of Bond Possible Dynamic Covalent Reactions 
C-C 
Aldol Reaction 
Diels-Adler Reaction 
Phenol/Aldehyde Condensation 
Friedel-Crafts Reaction 
Strecker Reaction 
Olefin Metathesis 
Alkyne Metathesis 
Carbene Coupling 
[2+1] Cycloaddition 
C-N 
C=N Formation/Exchanges 
Aminal Formation 
Amide Formation/Exchanges 
C-O 
Ester Formation/Exchanges 
Acetal Formation/Exchange 
Nicholas Ether-Exchange 
Hemiaminal Ether Exchange 
Alkyoxyamine Exchange 
C-S 
Thioacetal Exchange 
Thiazolidine Exchange 
Thia-Michael Reaction 
B-O Boronic Acid Condensation 
S-S Disulfide Exchange 
 
1.4.1 Thiol-Disulfide Exchange 
 Of the types of dynamic covalent reactions listed in Table 1, the disulfide 
exchange is of particular interest because of the biological significance it holds. 
Disulfide bonds play an important role as part of the building blocks utilized in 
protein folding (ie. the formation of secondary and tertiary structures) with both 
intra and inter subunit crosslinking reactions.54, 55 Additionally, disulfides are the 
major products of thiol oxidation, which is a biological process that’s primary role 
is defense mechanisms against oxidative stress, as well as redox controlled cell-cell 
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signaling.54 Disulfides are also key dynamic bonds responsible for many enzymes’ 
functionalities.54 This reaction is known to be highly robust, easily controllable, 
and dynamic, and may proceed in the presence of any supramolecular structure to 
create a reversible chemical system that is perhaps the most widely studied of any 
dynamic covalent reaction.55  
 This disulfide exchange reaction proceeds as a three-step mechanism that 
proceeds spontaneously, as demonstrated by Scheme 1.54, 55 
 
Scheme 1: Three step thiol-disulfide exchange reaction begins with a thiol 
deprotonated to form the nucleophilic thiolate anion which attacks a sulfur atom to 
form a new disulfide and thiolate anion. The former is then protonated to complete the 
mechanism 
This reaction proceeds by a simple SN2 type nucleophilic substitution with a single 
transition state, and no intermediate formation. There have been some studies that 
indicate this transition state is a linear trisulfide with the negative charge largely 
delocalized, but most abundant on the attacking and leaving sulfurs.54 This 
transition state can easily become too crowded and sterically hindered, so bulky 
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functional groups will not work for this reaction. However, sterics may also 
introduce strain on the disulfide bond which makes it more labile.   Recent studies 
suggest that the reaction is kinetically controlled, not thermodynamically, which 
indicates that redox potentials and equilibrium constants will only indicate whether 
the process is favorable, while the partitioning of particular pathways is rate 
dependent.54 There are several factors that influence the rate of disulfide exchange 
reactions, which are mainly focused on the pKa and nucleophilicity of the attacking 
thiol group, but anything that may affect the stability of the leaving group or the 
electrophilicity of the central disulfide sulfur are also important factors for 
decreasing the activation energy barrier.54 Examining the rate law and kinetic 
behavior of the reaction, it becomes clear that it cannot be fit to a simple first order 
exponential equation that yields the apparent rate constant (kapp).54 This is because 
disulfide exchanges will usually not reach completion, but rather a dynamic 
equilibrium in which both products and reactants are present.  
 Instead, the reaction is easily controlled by adjusting the pH.54-56 Although 
the reaction may proceed with an attacking thiol, the thiolate anion is a much 
stronger nucleophile, and so deprotonating the thiol (ie. pH > pKa)  is an easily 
controllable molecular trigger to initiate the reaction which occurs quickly under 
aqueous conditions.54-56 This molecular trigger is especially advantageous for 
creating responsive functional materials for applications in biotechnology and 
medicine because as previously mentioned in section 1.2.2, biological systems 
naturally vary in pH. For example, the tripeptide glutathione (GSH), for which the 
structure is shown in Figure 15, is a natural antioxidant found in both cytosolic fluid 
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of cells and plasma. It has been demonstrated that the concentration range of  
intracellular GSH is an order of magnitude higher than extracellular GSH 
(ie.approximately 1-10 mM, and 1-10 𝜇M, respectively).57, 58 Additionally, in tumor 
tissues, GSH concentration is even higher than that typically found in normal cell 
tissues. 
 
Figure 15: Chemical structure of glutathione (GSH) tripeptide structure in its reduced 
form is composed of y-glutamate, cysteine, and glycine amino acid residues and may 
serve as a nucleophile in disulfide exchange reactions 
This appreciable difference in concentration makes GSH a suitable trigger to 
stimulate release of an encapsulated payload in any nanocarrier, equip with a 
disulfide bond, that is taken up into cells.56-58 Triggered release is predicted to be 
more efficient in tumor cells than normal cells, as the higher GSH concentration in 
tumor cells makes the disulfide exchange reaction more favorable. Although the 
disulfide exchange reaction could theoretically occur at both intra- and extracellular 
GSH concentrations, it has been proven that disulfide bonds are quite stable in 
extracellular fluids, which is likely because the concentration of thiol is too low to 
elicit a reaction.58  
1.5 Nanomaterials  
 From antibacterial coatings for drug delivery to supramolecular and 
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dynamic covalent chemistry, nanomaterials (ie. materials with dimensions of 
approximately ≤100 nm) have been of heavily researched over the last century.59, 
60  This is, in part, due to the broad availability of nanoscale materials and the 
technological advances for characterizing them, but more so, controlling materials 
properties on the nanoscale is highly advantageous.59 Atoms do not behave the 
same way on the nanoscale as they do on the macroscopic scale. Hence, as the size 
of materials decreases, the scalability of the principles that govern macromolecular 
control over materials properties becomes quite challenging.60  However, the use of 
nanomaterials has enhanced bulk material properties in ways that were never before 
possible, which is why they are so exhaustively studied and applied in diverse 
applications. The main challenges with developing new nano-based macromaterials 
are specialized and financially draining characterization requirements, as well as 
concerns over health and safety.59, 60 New technology is making the former issue 
much more manageable, while the latter is still quite ambiguous. This is because 
the physiochemical effects of nanomaterials on human physiological systems and 
the environment is difficult to measure.59 It is presumed that since a very small 
change in intricacies such as size, shape, surface functionality, charge, etc on the 
nanoscale can elicit a large change in bulk material properties, that the same would 
be true of living beings and their surrounding environment. Therefore, thorough 
nanotoxicology studies are considered essential for the development of newly 
developed nanomaterials to ensure their safety with widespread use, especially in 
biotechnology and medicine.59 
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 1.5.1 Vesicle Loaded Gel Networks 
 Previous sections (ie. 1.1-1.4) have addressed recent advances and issues in 
some select topics of nanomaterials applications (ie. antibacterial coatings for drug 
delivery, supramolecular chemistry, and dynamic covalent chemistry), and 
although there have been remarkable developments in these fields individually, a 
multidisciplinary approach may offer even more. Individually, perhaps the two 
most promising candidates to create antibacterial coatings for drug delivery are 
hydrogels and vesicles. Taking a look at their advantages, as previously mentioned 
in sections 1.1.1 and 1.3.3.1, respectively, hydrogels demonstrate superior 
biocompatibility, mechanical strength, and adaptability to the external 
environment, largely owed to their porous crosslinking networks that allows them 
to absorb water up to hundreds of times their own volume. Likewise, vesicles 
demonstrate excellent encapsulation ability for both hydrophobic and hydrophilic 
drugs, controlled release in response to certain stimuli, and overall biocompatibility 
and stability. However, vesicles tend to suffer from rapid clearance in vivo while 
hydrogels tend to suffer from limited encapsulation ability and rapid release of 
encapsulated payloads.  
 Therefore, it is of interest to combine these two platforms to mitigate their 
individual issues and combine their advantages. In fact, there has been a lot of up-
and-coming research done in this field that has demonstrated that the mechanical 
strength and adaptability of  hydrogels tends to stabilize the vesicles and prevent 
rapid physiological clearance, while the vesicles tend to further stabilize the 
hydrogel matrix and prevent rapid released of encapsulated payloads.61-74 This 
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hybrid system also offers opportunities for implementing dual release mechanisms, 
one for the hydrogel and one for the vesicles, as well as encapsulation of more than 
one payload. The combination of supramolecular chemistry forming vesicles and 
dynamic covalent bonds for triggered release mechanisms and/or crosslinking 
network formation takes advantage of the programmed multivalent self-assembly 
of supramolecular amphiphiles with the robustness of dynamic covalent bonds to 
extend the applicability of both vesicles and hydrogels in drug delivery and 
coatings.  
1.6 Motivation and Research Plan 
 This study aims to create a novel antibacterial hydrogel coating by 
embedding vesicles into a hydrogel coating, as visualized in Figure 16.  
Figure 16: Schematic illustration of novel vesicle embedded hydrogel coating capable of 
encapsulating two different payloads, with dual sustained release mechanisms 
56 
 
This will mitigate burst release of encapsulated payload in the hydrogel, as well as 
stabilize the vesicles for a longer shelf life. Vesicles will be prepared from a novel 
supramolecular amphiphile composed of thio-alkyl modified 𝛽CD of varying chain 
lengths (ie. 12 and 14 carbon) as the macrocyclic host (ie. 𝛽CD-C12, 𝛽CD-C14), 
and an adamantyl-dicarboxylic acid-disulfide modified PEG (ie. AdSSPEG) with 
an average degree of polymerization (DP) of 22 as the linear guest, as demonstrated 
by Figure 17. This host-guest system will form inclusion complexes that self-
assemble spontaneously to bilayered vesicles in aqueous solutions, which decreases 
the number of synthetic steps to simplify preparation.  
Figure 17: Schematic illustration of thioalkyl modified 𝛽CD-Cn host including the 
adamantyl group of the AdSSPEG guest, which self assembles to form bilayers and then 
bilayered vesicles in aqueous solutions 
These vesicles will serve as three-dimensional multivalent junctions to form a 
hydrogel through crosslinking of thiolated PEG through a dynamic disulfide 
exchange reaction and will be capable of dual and selective release of two different 
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encapsulated payloads. Herein, the vesicles are capable of encapsulating 
hydrophobic or hydrophilic drugs in either its lipophilic bilayer membrane or 
aqueous interior cavity, respectively, while the hydrogel may also encapsulate a 
second drug during the crosslinking reaction. A pH sensitive acid labile bond 
embedded in the thiolated PEG (PEGdiSH) crosslinker will cleave under acidic 
conditions to release the payload enclosed in the hydrogel matrix, while a disulfide 
bond embedded in the supramolecular amphiphile of the free vesicle can be cleaved 
in the presence of GSH to release the second payload. 
Figure 18: AdSSPEG and 𝛽CD-Cn inclusion complexes form a supramolecular 
amphiphile that self-assembles to bilayered vesicles in aqueous solution. A) Vesicles are 
crosslinked by PEGdiSH to form a hydrogel coating with two payloads encapsulated within 
each of the vesicle and hydrogel during preparation B) Acidic environment will trigger the 
cleavage of acid labile silyl-ether bond to release encapsulated payload from the hydrogel 
medium C) Intracellular concentrations of glutathione will cleave the disulfide bond in the 
AdSSPEG guest and remove the hydrophilic PEG to disrupt the ideal HLB and cause 
release of encapsulated payload in the vesicle 
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 In this study, we will determine the ideal conditions for preparing the vesicle 
loaded hydrogel coating and fully characterize the individual components as well 
as the end product(s). The overall schematic is demonstrated by Figure 18. 
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2. EXPERIMENTAL METHODS AND MATERIALS  
2.1 Materials 
 All materials were used as received, unless otherwise stated. 𝛽-
Cyclodextrin (𝛽CD), triphenylphosphine (PPh3), 1-tetradecanethiol, 1-
dodecanethiol, poly(ethylene glycol) (PEG; molecular weights 2000, 3400, 4000, 
10000, and 20000 g/mol), anhydrous dichloromethane (DCM), anhydrous 
tetrahydrofuran (THF), poly(ethylene glycol)-methyl ether (PEGOMe; molecular 
weight 1000 g/mol), triethylamine (TEA), and nile red were purchased from TCI 
Chemicals. Anhydrous dimethylformaldehyde (DMF), potassium-tert-butoxide (K-
t-butoxide), acetyl chloride, 3,3-dithiopropionic acid (DTDP), 4-
dimethylaminopyridine (DMAP), 1-adamantol, and 5,6-carboxyfluorescin were 
purchased from Acros Organics. Triton X-100, sephadex G-50, PEG (molecular 
weights 200, and 1000 g/mol), and liquid bromine (Br2 (l)) were purchased from 
Sigma Aldrich. L-glutathione (reduced), N,N’-dicyclocarbodiimide (DCC), and p-
toluenesulfonyl chloride (TsCl) were purchased from Alfa Aesar. Anhydrous 
pyridine was purchased from DriSolv. Thiourea was purchased from MCB. 
Magnesium sulfate (MgSO4), and tris base were purchased from Fisher Chemical. 
Polycarbonate 200 nm pore size membrane was purchased from Avanti Polar 
Lipids, Inc. All other solvents and materials were received and/or prepared from 
the Cal Poly Organic Chemistry Stockroom.  
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2.2 Synthesis of Thioalkyl Modified 𝜷-Cyclodextrins (𝜷CD-C12, 𝜷CD-
C14) 
 2.2.1 Synthesis of Heptakis(6-bromo)- 𝜷CD 
 
Figure 19: Chemical structure of [1] Heptakis(6-bromo)-	𝛽CD 
 Native 𝛽-CD (4.0 g, 3.5 mmol) was dried over molecular sieves with 
anhydrous DMF (≈20 mL) overnight (≈18 hours). The solution was transferred to 
a round bottom flask, and solvent along with any residual water was removed under 
reduced pressure. PPh3 (20 eq.) was added to a round bottom flask, dissolved in 
anhydrous DMF (≈20 mL), and purged under nitrogen three times. Br2 (l) (20 eq.) 
was then added dropwise to the PPh3 solution via nitrogen purged syringe and 
stirred at 60 ℃ for 30 minutes. Dry 𝛽-CD was dissolved in anhydrous DMF (≈10 
mL) and was then added to the reaction mixture dropwise and stirred overnight 
(≈18 hours) at 80 ℃. Approximately half the solvent volume was then removed 
under reduced pressure, and the resulting reaction mixture was added to methanol 
(≈100 mL). The pH was adjusted to 10-12 with K-t-butoxide and the resulting 
reaction mixture was stirred at room temperature for 30 minutes. This reaction 
mixture was then precipitated in rapidly stirring ice-cold deionized water (DI 
water). The precipitate was isolated via vacuum filtration, transferred to a falcon 
tube, and then dissolved in methanol. The resulting solution was centrifuged 
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(Eppendorf, Centrifuge 5810) three times in 5-minute intervals at 7500 RPM. 
Methanol was decanted and the precipitate was transferred to a round bottom flask 
and dissolved in a minimal amount of DMF. The solvent was then removed under 
reduced pressure. Product was dried under high vacuum pump overnight (≈18 
hours) to obtain a white powder [1]. 
2.2.2 Synthesis of Heptakis(6-dodecylthiol)- 𝜷CD (𝜷CD-C12), 
Heptakis(6-tetradecylthiol)- 𝜷CD (𝜷CD-C14) 
 
Figure 20: Chemical structure of [2a] Heptakis(6-dodecylthiol- 𝛽CD, and [2b] 
Heptakis(6-tetradecylthiol)- 𝛽CD 
 Brominated 𝛽-CD [1] (350 mg, 0.22 mmol), either 1-dodecanethiol (for 
[2a]) or 1-tetradecanethiol (for [2b]) (20 eq.), and K-t-butoxide (20 eq.) were 
combined and purged under nitrogen three times. Anhydrous DMF (≈20 mL) was 
added via nitrogen purged syringe to dissolve all reagents, and was allowed to stir 
for 72 hours at 80 ℃. The reaction mixture was then precipitated in rapidly stirring 
ice cold DI water. The precipitate was isolated via vacuum filtration, and 
transferred to a round bottom flask. The precipitate was then refluxed (65 ℃) in 
methanol (≈20 mL) for 1 hour. The resulting precipitate was isolated by vacuum 
filtration and washed with hot methanol. The product was dried under high vacuum 
pump overnight (≈18 hours) to obtain a white powder (n = 12) [2a] 1H NMR (400 
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MHz, Chloroform-d) δ 6.71 (s, 1H), 5.24 (s, 1H), 4.98 (s, 1H), 3.99 (t, 1H), 3.92 (t, 
1H), 3.74 (t, 1H), 3.49 (t, 1H), 3.05 (d, 1H), 2.88 (m, 1H), 2.60 (t, 2H), 1.57 (m, 
12H), 1.26 (m, 51H), 0.88 (t, 8H), or (n = 14) [2b] 1H NMR (400 MHz, Chloroform-
d) δ 6.71 (s, 1H), 5.24 (s, 1H), 4.97 (s, 1H), 3.99 (t, 1H), 3.91 (t, 1H), 3.74 (t, 1H), 
3.49 (t, 1H), 3.04 (d, 1H), 2.88 (m, 1H), 2.60 (t, 2H), 1.55 (m, 15H), 1.25 (m, 29H), 
0.88 (t, 4H). 
 2.3 Synthesis of Adamantyl-Dithiopropionic acid Modified 
Poly(ethylene-glycol) / Poly(ethylene glycol)-methyl ether (AdSSPEG / 
AdSSPEGOMe) 
 2.3.1 Synthesis of Dithiopropionic Anhydride 
 
Figure 21: Chemical structure of [3] Dithiopropionic anhydride 
 DTDP (2.10 g, 10 mmol) was added to a round bottom flask and refluxed 
(65 ℃)  in acetyl chloride (10 eq.) for 2 hours. The reaction mixture was cooled to 
room temperature, and acetyl chloride was removed under reduced pressure. The 
resulting residue was precipitated in rapidly stirring ice-cold diethyl ether. 
Precipitate was then isolated via vacuum filtration and washed with ice cold diethyl 
ether. The product was dried under high vacuum pump overnight (≈18 hours) to 
obtain an off-white powder [3].  
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2.3.2 Synthesis of Dithiopropionic acid Modified Poly(ethylene glycol) 
/ Poly(ethylene glycol)-methyl ether 
 
Figure 22: Chemical structure of [4a] Dithiopropionic acid-Poly(ethylene glycol), and 
[4b] Dithiopropionic acid-Poly(ethylene glycol)-methyl ether 
 Either PEG (for [4a]) or PEGOMe (for [4b]) (6.5 g, 6.5 mmol) was dried 
over molecular sieves with anhydrous DMF (≈20 mL) overnight (≈18 hours). The 
solution was transferred to a round bottom flask, and solvent along with residual 
water was removed under reduced pressure. Dithiopropionic anhydride [3] (2 eq.), 
and DMAP (1 eq.) were added to the round bottom flask and all reagents were 
dissolved in anhydrous DMF (≈20 mL). TEA (2 eq.) was added dropwise. The 
resulting solution was purged under nitrogen three times and allowed to stir at 35 ℃ for 36 hours. The reaction mixture was then precipitated in rapidly stirring ice-
cold diethyl ether. The precipitate was isolated via vacuum filtration and washed 
with ice cold diethyl ether. The product was then dried under high vacuum pump 
overnight (≈18 hours) to obtain a brown powder [4a] or [4b].  
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2.3.3 Synthesis of Adamantyl-Dithiopropionic acid Modified 
Poly(ethylene-glycol) / Poly(ethylene glycol)-methyl ether (AdSSPEG / 
AdSSPEGOMe) 
 
 
Figure 23: Chemical structure of [5a] Adamantyl-Dithiopropionic acid-
Poly(ethylene-glycol) (AdSSPEG), and [5b] Adamantyl-Dithiopropionic acid-
Poly(ethylene-glycol)-methyl ether (AdSSPEGOMe) 
 Dithiopropionic acid-PEG [4a] or dithiopropionic acid-PEGOMe [4b] (7 g, 
5.87 mmol) was co-dissolved with 1-adamantol (2 eq.) in anhydrous DCM (≈20 
mL) at 0 ℃. In a separate round bottom flask, DCC (2 eq) was also dissolved in 
anhydrous DCM (≈ 5 mL) at 0 ℃. Both solutions were then purged under nitrogen 
three times. DCC solution was added to the initial solution dropwise and stirred for 
2 hours at 0 ℃. The reaction mixture was then allowed to stir for 22 hours at room 
temperature. By product N,N’-dicyclourea (DCU) was removed by gravity 
filtration. The filtrate was washed three times with 10% hydrochloric acid (HCl). 
The aqueous layer was extracted with DCM until the organic layer appeared clear 
(≈6 times). The organic layer was then washed three times with brine and dried 
over MgSO4. The solvent was then removed under reduced pressure. The resulting 
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residue was precipitated in rapidly stirring ice-cold heptane, isolated via vacuum 
filtration, and washed with ice cold ether. The product was further purified in DI 
water via dialysis (Float-A-Lyzer G2) with a 0.1-0.5 kDa pore membrane. The 
resulting solution was flash-frozen with liquid nitrogen and left on the lyophilizer 
(Labconco, FreeZone 4.5) overnight (≈18 hours) to remove water and obtain a 
yellow-orange powder [5a] 1H NMR (400 MHz, DMSO-d6) δ 5.62 (s, 4H), 3.49 (s, 
3H), 3.43 (s, 2H), 3.34 (s, 38H), 2.88 (s, 4H), 2.62 (s, 4H), 2.03 (s, 11H), 1.73 (s, 
10H), 1.58 (s, 62H), or [5b] 1H NMR (400 MHz, Chloroform-d) δ 3.82 (s, 1H), 3.71 
(s, 6H), 3.65 (s, 199H), 3.56 (s, 5H), 3.38 (s, 6H), 2.92 (s, 4H), 2.77 (s, 3H), 2.14 
(s, 15H), 1.71 (s, 18H), 1.63 (s, 27H). 
2.4 Synthesis of Thiol Modified Poly(ethylene-glycol) (PEG-diSH) 
 2.4.1 Synthesis of Poly(ethylene glycol)-di(p-toluenesulfonic acid) 
(PEGdiOTs) 
 
 
Figure 24: Chemical structure of [6] Poly(ethylene glycol)-di(p-toluenesulfonic acid) 
(PEGdiOTs) (n = 22 [6a], 45 [6b], 77 [6c], 90 [6d], 227 [6e], 454 [6f]) 
 PEG (n = 22 [6a], 45 [6b], 77 [6c], 90 [6d], 227 [6e], 454 [6f], 1.5 mmol) 
was dried over molecular sieves with anhydrous DMF (≈20 mL) overnight (≈18 
hours). The solution was transferred to a round bottom flask, and solvent along with 
any residual water was removed under reduced pressure. TsCl (4 eq.) was added 
and the resulting mixture was purged under nitrogen three times. Anhydrous 
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pyridine (10 eq.) was then added at 0 ℃, and all reagents were dissolved in 
anhydrous DCM (≈20 mL). The reaction mixture was stirred overnight (≈18 hours) 
at 0 ℃. Three pieces of 7 cm diameter cellulose-based filter paper were cut up into 
small pieces and added to the solution. The reaction mixture was then sonicated 
(Ultrasonic Cleaner, GB-928) at 40 kHz for 1 hour to remove excess TsCl. The 
filter paper was removed, and the reaction mixture was washed three times with 
10% HCl. The aqueous layer was extracted with DCM until the organic layer 
appeared clear (≈6 times). The organic layer was washed three times with brine 
and dried over MgSO4. The solvent was removed under reduced pressure, and the 
product was dried overnight (≈18 hours) under a high vacuum pump to obtain a 
slightly yellow oil (n = 22 [6a]), or a slightly yellow powder (n = 45 [6b], 77 [6c], 
90 [6d], 227 [6e], 454 [6f]).  
 2.4.2 Synthesis of Poly(ethylene glycol)-dithiol (PEGdiSH) 
 
Figure 25: Chemical structure of [7] Poly(ethylene glycol)-dithiol (PEGdiSH) (n = 
22 [7a], 45 [7b], 77 [7c], 90 [7d], 227 [7e], 454 [7f]) 
 PEGdiOTs (n = 22 [6a], 45 [6b], 77 [6c], 90 [6d], 227 [6e], 454 [6f], 1 mmol) 
was co-dissolved with thiourea (6 eq.) in anhydrous THF (≈ 15 mL) in a round 
bottom flask. The resulting solution was purged under nitrogen three times and 
allowed to reflux (66 ℃) overnight (≈18 hours). The reaction mixture is cooled to 
room temperature and 10% NaOH (≈ 10 mL) was added through the top of the 
condenser. The reaction mixture was again allowed to reflux (66 ℃) overnight (≈18 
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hours). Once the layers separated, the organic layer solvent was removed under 
reduced pressure and the aqueous layer was extracted three times with DCM. The 
organic residue was dissolved in DI water, and the pH is adjusted to 7 with 10% 
HCl. The organic layer was then extracted three times with DCM. All organic layers 
were combined and washed three times with brine before drying over MgSO4. 
Solvent was removed under reduced pressure and the product was dried under high 
vacuum pump overnight (≈18 hours) to obtain a slightly yellow oil (n = 22) [7a] 
1H NMR (400 MHz, Chloroform-d) δ 3.81 (q, J = 4.6 Hz, 4H), 3.65 (s, 551H), 3.51 
– 3.43 (m, 4H), 2.88 (s, 4H), 1.89 (s, 43H), or a slightly yellow powder (n = 45) 
[7b] 1H NMR (400 MHz, Chloroform-d) δ 3.85 – 3.79 (m, 17H), 3.64 (s, 2567H), 
3.51 – 3.43 (m, 18H), 2.88 (s, 4H), 1.80 (s, 451H), (n = 77) [7c] 1H NMR (400 
MHz, Chloroform-d) δ 3.85 – 3.79 (m, 17H), 3.66 (s, 2483H), 3.49 – 3.44 (m, 18H), 
2.88 (s, 4H), 1.43 (s, 4H), (n = 90) [7d] 1H NMR (400 MHz, Chloroform-d) δ 3.82 
(dd, J = 5.8, 4.1 Hz, 4H), 3.64 (s, 995H), 3.47 (dd, J = 5.7, 4.1 Hz, 6H), 2.82 (s, 
4H), 1.65 (s, 150H), (n = 227) [7e] 1H NMR (400 MHz, Chloroform-d) δ 3.85 – 
3.78 (m, 15H), 3.65 (s, 2206H), 3.50 – 3.43 (m, 16H), 2.79 (s, 4H), 1.43 (s, 1H,  (n 
= 454) [7f]) 1H NMR (400 MHz, Chloroform-d) δ 3.85 – 3.79 (m, 16H), 3.65 (s, 
6453H), 3.49 – 3.44 (m, 71H), 2.69 (s, 4H), 1.43 (s, 1H). 
2.5 Nuclear Magnetic Resonance (NMR) Measurements 
 NMR (Bruker Ascend, 400 mHz) samples were prepared with 
approximately 10 mg of compound dissolved in an appropriate solvent. 
Compounds [2a, 2b, 5a, 5b, 7a-f] were analyzed via 1H NMR to confirm that final 
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products were formed as expected. Novel compounds [5a, 5b] were also analyzed 
via 13C NMR, and HSQC. MestreNova software was used to process all raw data. 
2.6 Fourier-Transform Infrared (FTIR) Measurements  
 The  FTIR (Perkin Elmer, Spectrum 100) crystal was cleaned with 2-
propanol and allowed to dry under ambient conditions. A background spectrum was 
then recorded. Samples were deposited onto the crystal in order to cover it. Novel 
compounds [5a, 5b] were analyzed for %Transmittance.  
2.7 Inclusion Complex Formation 
 Host and guest (ie. thioalkyl modified βCD [2a, 2b] host, and adamantyl-
dithiopropionic acid modified PEG / PEGOMe [5a, 5b] guest) were combined in 
equimolar amounts (5 µmol) in a round bottom flask with DI water (≈ 2 mL) and 
sonicated (Ultrasonic Cleaner, GB-928) at 40 kHz for 30 minutes. The solvent was 
removed under reduced pressure to afford a thin film. The film was hydrated with 
1:1 chloroform: DI water (≈ 2 mL total) and were again sonicated (Ultrasonic 
Cleaner, GB-928) at 40 kHz for 30 minutes. The solvent was removed under 
reduced pressure to afford the thin film inclusion complex. Inclusion complexes 
were stable and stored in the fridge.  
2.8 Vesicle Formation 
 Thin film inclusion complex was rehydrated with Tris buffer (10 mM Tris 
base, 10 mM NaCl, pH 7.40, ≈ 1 mL) and allowed to sit for 30 minutes at room 
temperature. This buffer solution was subjected to five freeze-thaw (liquid 
nitrogen-55 ℃ water bath) cycles to form vesicles, and was then probe sonicated 
(QSonica Sonicators, Ultrasonic Processor) at 20 kHz for 2 minutes to break up 
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larger aggregates. The solution was pushed through a 450 nm filter and then 
extruded (Avanti Polar Lipids, Inc.) ten times with a 200 nm pore size 
polycarbonate membrane (Avanti Polar Lipids, Inc.). Purified vesicles were stable 
for several weeks to a month and stored in the fridge.  
2.9 Fluorescent Vesicle Formation 
 Thin film hydration method from section 2.8 was used with 5,6-
carboxyfluorescin (CF) buffer (50 mM CF, 10 mM Tris base, 10 mM NaCl, pH 
7.40, ≈ 1 mL) instead of Tris buffer. After extrusion, fluorescent vesicles were 
further purified with size exclusion chromatography using a sephadex G-50 
column. The column was prepared in a 5 mL syringe with 1:10 sephadex G-50: Tris 
buffer. Sephadex G-50 was allowed to settle to the 3 mL mark before adding vesicle 
containing CF buffer solution. The column was then eluted with Tris buffer, and a 
fraction was collected for each colored band. Vesicles were in the orange band. 
Vesicles with encapsulated CF were stored in the fridge. The column was reused 
once all fluorescent dye had been eluted from the column.  
2.10 Fluorimeter Measurements 
 Fluorimeter (Horiba Scientific, Fluorolog-QM) was set to the appropriate 
experimental parameter and run at room temperature. Sample was loaded into a 
quartz cuvette with a stir bar and stirred at speed 5 during all measurements. 
FluorEssenceTM software was used for all data analysis.  
 2.10.1 Fluorescent Vesicle Encapsulation and Lysing via Fluorimetry 
 Fluorimeter (Horiba Scientific, Fluorolog-QM) was set to kinetics 
acquisition with 𝜆=>	= 517 nm with a slight width of 1 nm, and 𝜆=? = 492 nm with 
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a slit width of 1 nm for fluorescent probe CF. Total run time was 90 seconds with 
data collection every 0.1 seconds. Fluorescent vesicles prepared according to the 
method in section 2.9 were diluted with Tris buffer (25 𝜇L vesicles, 2000 𝜇L Tris 
buffer) and pipetted up and down to mix. Sample was then allowed to equilibrate 
for 30 seconds before measurements were taken. The kinetics acquisition was 
initiated, and a baseline was established for 30-40 seconds before adding 250 𝜇L 
of 10% Triton X-100 detergent to lyse the vesicles. The percent change in 
fluorescence intensity (%ΔFluorescence Intensity) was calculated using Equation 
1, where 𝐼C = Fluorescence Intensity (CPS) at time t, and 𝐼D = Fluorescence Intensity 
(CPS) at time 0.   
 
         %	∆𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒	𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 = 	 (STU	SV)	SV ∗ 100                     EQ. 1  
 
 Results from this calculation determine whether vesicles were formed and 
whether they encapsulated CF in their interior. A high %ΔFluorescence Intensity 
comparing inclusion complexes, and host and guest molecules on their own (treated 
with the same fluorescent vesicle formation method in section 2.9) was indicative 
of successful vesicle formation and CF encapsulation.  
 2.10.2 Critical Aggregation Concentration (CMC) via Fluorimetry 
 Fluorimeter (Horiba Scientific, Fluorolog-QM) was set to spectra 
acquisition with 𝜆=? = 515 nm with a slit width of 7 nm and 𝜆=>	= 530 – 670 nm 
with a slit width of 7 nm for fluorescent probe nile red. Samples were prepared at a 
broad range of supramolecular amphiphile (ie. thioalkyl modified βCD [2a, 2b] 
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host, and adamantyl-dithiopropionic acid modified PEG / PEGOMe [5a, 5b] guest 
inclusion complexes) concentrations (0 – 500 𝜇M) with nile red concentration held 
constant at 0.156 𝜇g/mL. Nile red stock solution (5 𝜇g/mL) was prepared in DCM 
and was added to 5 mL volumetric flasks. Solvent was evaporated from the flasks 
before amphiphile addition. Amphiphile was then added at the appropriate amount 
and the sample was diluted to volume with nanopure water (Thermo Scientific, 
Barnstead GenPure, 18.20 MΩ*cm). Each sample was sonicated (Ultrasonic 
Cleaner, GB-928) at 40 kHz for 10 minutes and was then stored in vials for a few 
hours before fluorimeter measurements were taken to allow for equilibration. 
Fluorimeter measurements were taken in triplicate for each sample, and 𝜆>\? and 
the Fluorescence Intensity (CPS) at 𝜆>\? were recorded.  
 Nile red behaves differently in aqueous environments versus lipophilic 
environments, so when amphiphiles begin to form micelles the nile red will be 
encapsulated in the hydrophobic interior and fluoresce at a higher wavelength and 
intensity than in aqueous solutions.75 Therefore, by plotting fluorescence intensity 
(CPS) at 𝜆>\? against amphiphile concentration (𝜇M), the slope approaches 0 at 
the critical micelle concentration (CMC). Two linear fits can be made before (0) 
and after (f) the CMC. Finding the intersection of these lines via Equation 2 will 
give CMC (x).  
 (𝑚𝑥 + 𝑏)a = (𝑚𝑥 + 𝑏)D                                          EQ. 2 
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2.11 Dynamic Light Scattering (DLS) Measurements 
 Dynamic light scattering (DLS) (Wyatt Tech, DynaPro NanoStar) 
measurements were taken in disposable cuvettes in a dust free environment. The 
cell temperature was set to 25 ℃ and the solvent was set to water for all samples. 
If samples were clear, 100 𝜇L was loaded into the cuvette without scratching the 
sides, the cap was placed, and measurements were taken after a 30 second 
equilibration time. If samples were not clear, they were diluted with nanopure water 
(Thermo Scientific, Barnstead GenPure, 18.20 MΩ*cm) until clear and loaded as 
previously mentioned. For all samples, the average of 20 scans was used for data 
collection and %Intensity, %PD (polydispersity), and hydrodynamic radius (nm) 
were recorded. The sample was then aspirated out of the cuvette, and the cuvette 
was rinsed several times with nanopure water (Thermo Scientific, Barnstead 
GenPure, 18.20 MΩ*cm) before re-use.   
2.11.1 Vesicle Particle Size via DLS 
 Vesicles prepared according to section 2.8 were measured on DLS (Wyatt 
Tech, DynaPro NanoStar) according the method previously mentioned in section 
2.11. To determine relative stability of vesicles, all vesicle samples were measured 
repeatedly over the course of several weeks. 
2.11.2 Vesicle Glutathione (GSH) Degradation via DLS 
 Vesicles prepared according to section 2.8 (with the modification of Tris 
buffer pH = 8.5) were measured on DLS (Wyatt Tech, DynaPro NanoStar) 
according the method previously mentioned in section 2.11. Initial measurements 
were recorded, and then vesicle particle size stability was tested first with 10% 
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Triton X-100, and then intracellular and extracellular concentrations of glutathione 
(GSH). For 10% Triton X-100 degradation experiments, a 25 𝜇L aliquot of vesicles 
was added to a vial with 2000 𝜇L of Tris buffer and 250 𝜇L 10% Triton X-100. 
Sample was mixed by hand and measurements were taken immediately according 
to the method previously mentioned in section 2.11. For intracellular [GSH] 
degradation experiments, a GSH buffer (500 mM GSH, 10 mM Tris base, 10 mM 
NaCl, pH 8.5) was prepared. A 25 𝜇L aliquot of vesicles was added to a vial with 
2000 𝜇L of Tris buffer and 50 𝜇L of GSH buffer to give a final [GSH] = 12 mM, 
which is just above the intracellular GSH range.57, 58 Samples were orbit mixed for 
1 hour, and then overnight (≈18 hours), and measurements were taken at each time 
increment according to the method previously mentioned in section 2.11. For 
extracellular [GSH] degradation experiments, a GSH buffer (1 mM GSH, 10 mM 
Tris base, 10 mM NaCl, pH 8.5) was prepared. A 25 𝜇L aliquot of vesicles was 
added to a vial with 2000 𝜇L of Tris buffer and 40 𝜇L of GSH buffer to give a final  
[GSH] = 20 𝜇M, which is just above the extracellular GSH range.57, 58 Samples were 
orbit mixed for 1 hour, and then overnight (≈18 hours), and measurements were 
taken at each time increment according to the method previously mentioned in 
section 2.11. Initial measurements were compared to the measurements with 10% 
Triton X-100, intracellular, and extracellular [GSH] to determine if any vesicle 
degradation had occurred.  
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2.12 Hydrogel Formation 
 Hydrogel formation was attempted with all vesicles prepared according to 
section 2.8, and all PEGdiSH [7a-f] crosslinkers of varying molecular weight (ie. 
1000, 2000, 3400, 4000, 10000, and 20000 g/mol).  
 Initial experiments were done at pH 7.4 at room temperature and PEGdiSH 
wt/wt% 0.5, 1.0, 2.5, and 5.0 where PEGdiSH wt/wt% was calculated according to 
Equation 3. Vesicle amount was held constant at 250 𝜇L.  
 𝑃𝐸𝐺𝑑𝑖𝑆𝐻	𝑤𝑡/𝑤𝑡% = 	j=klmC	na	opqrkst	uvaa=wj=klmC	na	CnC\x	uvaa=w ∗ 100              EQ. 3                      
 
Samples were prepared by combining vesicles in Tris buffer and PEGdiSH buffer 
(1 mM PEGdiSH, 10 mM Tris base, 10 mM NaCl, pH 7.4) in the appropriate 
amounts. Samples were vortex mixed for 30 seconds, and then orbit mixed 
overnight (≈18 hours). Samples were checked every hour for 3 hours, and then 
again after 24 hours, for hydrogel formation by inverting the vial to see if it can 
hold its own weight. 
 Additional experiments were done at pH 8.5 at room temperature at 
PEGdiSH wt/wt% 1.0, 2.5, 5.0, 10, and 20 where PEGdiSH wt/wt% was calculated 
according to Equation 3. Vesicle amount was held constant at 250 𝜇L. Samples 
were prepared by combining vesicles in pH modified Tris buffer (pH 8.5) and 
PEGdiSH buffer (1 mM PEGdiSH, 10 mM Tris base, 10 mM NaCl, pH 8.5) in the 
appropriate amounts. Samples were vortex mixed for 30 seconds, and then orbit 
mixed overnight (≈18 hours). Samples were checked every hour for 3 hours, and 
75 
 
then again after 24 hours, for hydrogel formation by inverting the vial to see if it 
can hold its own weight. 
 Further experiments were done with the aforementioned 20 wt/wt% 
PEGdiSH containing samples. These samples were incubated at temperatures 30, 
35, 40, 45, and 50 ℃ for 2 hours each, and checked for hydrogel formation every 
30 minutes by inverting the vial to see if it can hold its own weight. 
 Final experiments were done at pH 8.5, temperatures 25, 35, 45 and 55 ℃, 
and PEGdiSH wt/wt% 10 and 20, where PEGdiSH wt/wt% was calculated 
according to Equation 4. Vesicle amount was gradually increased after each 
temperature incubation from 10, 20, 40, 60, 80, 100, to 250 𝜇L. PEGdiSH amount 
was held constant at 250 𝜇L. 
 𝑃𝐸𝐺𝑑𝑖𝑆𝐻	𝑤𝑡/𝑤𝑡% = 	 j=klmC	opqrkstj=klmC	na	ywkz	uvaa=w ∗ 100                     EQ. 4              
 
Samples were prepared by combining vesicles in pH modified Tris buffer (pH 8.5) 
and PEGdiSH in pH modified Tris buffer (pH 8.5) in the appropriate amounts. 
Samples were vortex mixed before being allowed to incubate at each of the 
previously mentioned temperatures for 1 hour each and are checked for hydrogel 
formation every 30 minutes by inverting the vial to see if it can hold its own weight. 
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3. RESULTS AND DISCUSSION 
3.1 Synthesis of Thioalkyl Modified 𝜷-Cyclodextrins (𝜷CD-C12, 𝜷CD-
C14)     
 Thioalkyl modified 𝛽CDs [2a, 2b] were synthesized according to Scheme 2 
and were characterized via 1H NMR to confirm that the macrocyclic host molecules 
were formed as expected.  
  
 
Scheme 1: Synthesis of [1] Heptakis(6-bromo)- 𝛽CD, and [2] Heptakis(6-thioalkyl)- 𝛽CD  
(n= 12 [2a], 14 [2b]) 
After the initial bromination at position 6 of the native 𝛽CD, the thioalkyl chain 
was covalently attached via an SN2 substitution reaction. Products [2a, 2b] were 
then isolated via a hot methanol reflux, filtration, and centrifugation to remove 
excess unreacted free thiol from the precipitate. It was found that increasing 
reaction times  increased the overall yield from this synthetic pathway, and 
persistent centrifugations in addition to vacuum filtrations were effective methods 
[1] 
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O
HO
OH
OH
O 7
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77 
 
to purify the final products [2a, 2b]. Hot methanol filtration and washing in the final 
step was essential in removing free unreacted alkyl thiol. 
 
Figure 26: 1H NMR of βCD-C12 [2a] in deuterated chloroform (CDCl3)   
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Figure 27: 1H NMR of βCD-C14 [2b] in deuterated chloroform (CDCl3) 
 
 Proton NMRs in Figures 26 and 27 correspond to 𝛽CD-C12 [2a] and 𝛽CD-
C14 [2b], respectively. Here, peaks labeled a, b, c, d, and e correspond to protons 
within the core glucose structure. Peak f corresponds to protons at position 6 where 
the thioalkyl chain has been covalently bound. The triplet peak g corresponds to the 
protons directly besides the sulfur atom, as they are downfield due to deshielding 
effect from the sulfur. The appearance of this peak at 2.60 ppm was used to confirm 
final product formation. Peak h corresponds to the rest of the protons on the 
thioalkyl chain, while peak i corresponds to the terminal methyl protons. Overall, 
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both 𝛽CD-C12, 𝛽CD-C14 [2a, 2b] were synthesized successfully and in good yield 
(78-86%).  
 In Figure 26, excess free unreacted alkyl thiol was still present in the final 
product, but it is in such a small amount compared to the 𝛽CD-C12 [2a] product 
that the material was deemed pure enough for use in subsequent experiments. 
Additionally, the excess alkyl thiol does not have the necessary amphiphilicity and 
geometry needed to form inclusion complexes or self-assemble on its own, so it is 
not a concern for interfering with subsequent experiments. The 𝛽CD-C12, and 𝛽CD-C14 [2a, 2b] products on their own have very poor water solubility which can 
be attributed to the hydrophobic thioalkyl modification along with the hydrophobic 
core of the truncated cone structure. However, the exterior of the truncated cone 
structure is hydrophilic due to the stereochemistry of the abundant hydroxyl groups 
on the core glucose structure facing outwards, which overall makes these 
macrocyclic host molecules amphiphilic on their own.  
3.2 Synthesis of Adamantyl-Dithiopropionic acid Modified Poly(ethylene-
glycol) (AdSSPEG, AdSSPEGOMe)   
 Novel adamantyl-dithiopropionic acid modified poly(ethylene glycol)s 
(AdSSPEG, AdSSPEGOMe) [5a, 5b] were synthesized according to Scheme 3 and 
4 and characterized via 1H NMR, 13C NMR, HSQC, and FTIR to confirm that linear 
guest molecules were synthesized as expected. 
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Scheme 2: Synthesis of [3] Dithiopropionic anhydride, [4a] Dithiopropionic acid-
poly(ethylene glycol), and [5a] Adamantyl-dithiopropionic acid-poly(ethylene glycol) 
(AdSSPEG) 
 
 
 
 
Scheme 3: Synthesis of [3] Dithiopropionic anhydride, [4b] Dithiodipropionic acid-
poly(ethylene glycol)-methyl ether, and [5b] Adamantyl-dithiopropionic acid-
poly(ethylene glycol)-methyl ether (AdSSPEGOMe) 
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Initially, DTDP was cyclized to form an anhydride. The anhydride ring was then 
opened via alcohol addition to covalently attach PEG (for [5a]) or PEGOMe (for 
[5b]). DCC was used as a coupling agent to attach an adamantane group to the 
terminal carboxylic acid of [4a] or [4b] to form the final product [5a] or [5b]. The 
first two steps of this synthetic pathway were simple and straightforward to execute 
in practice, while the final step required much more effort to isolate a pure final 
product due to the strong amphiphilicity of the linear guest molecules creating 
solubility challenges. PEG / PEGOMe molecules of 1000 g/mol were used because 
PEG with lower molecular weights are much more soluble in diethyl ether, and 
hence much more difficult to isolate via precipitation as a purification method. 
Additionally, lyophilizing the final product after dialysis was instrumental in 
removing all excess water and obtaining a pure product. Due to the amphiphilicity 
of the products, water was unable to be completely removed via rotary evaporation. 
Lyophilization was preferable because it converts water straight from the solid 
phase to the gas phase, while rotary evaporation converts water from the liquid 
phase to the gas phase. This is because the solid to gas transition occurs at a much 
lower temperature than the liquid to gas transition which decreases the amphiphilic 
molecules’ ability to hold onto water molecules. 
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Figure 28:  1H NMR of AdSSPEGOMe [5b] in deuterated chloroform (CDCl3) 
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Figure 29: 1H NMR of AdSSPEG [5a] in deuterated dimethylsulfoxide (DMSO) 
 
 Proton NMRs in Figures 28 and 29 correspond to AdSSPEGOMe and 
AdSSPEG [5b, 5a], respectively. Here, peaks labeled g and h correspond to protons 
within the adamantane group structure. Peak a corresponds to protons within the 
ethylene glycol repeat group, while peak b corresponds to the end group. For 
AdSSPEGOMe, this is three methyl protons, while for AdSSPEG this is one 
hydroxyl proton. Hydroxyl protons are known to have unreliable and broad 
chemical shifts (if they show up at all), so although the integration for the hydroxyl 
proton indicates four protons, it is actually just one. Peaks c and d correspond to 
the protons between the repeat group and the ester linkage, which were used to 
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confirm that the final product formed. The nearby oxygens on the ester group 
deshield these protons which pushes them slightly downfield of the rest of the PEG 
protons. Similarly, peaks f and e correspond to protons between the ester and 
disulfide linkages, where the disulfide group is less deshielding than the 
surrounding oxygens which results in these triplet peaks being upfield the PEG 
protons.  
 
 
Figure 30: 13C NMR of AdSSPEGOMe [5b] in deuterated chloroform (CDCl3) 
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Figure 31: 13C NMR of AdSSPEG [5a] in deuterated dimethylsulfoxide (DMSO) 
 
 Carbon NMRs in Figures 30 and 31 correspond to AdSSPEGOMe and 
AdSSPEG [5b, 5a], respectively. Here, carbonyl peaks labeled C=O correspond to 
the two ester peaks in the core of the guest molecule structure. They exhibit 
different chemical shifts as they are not equivalent due to the adamantyl linkage on 
one and PEG linkage on the other having different electron densities. The PEG 
group electron density is much lower than that of the adamantane group, which 
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causes the ester carbon attached to the PEG group to be more deshielded and appear 
slightly downfield from the ester carbon attached to the adamantane group.  
 
Figure 32: HQSC two-dimensional NMR of AdSSPEGOMe [5b] in deuterated chloroform 
(CDCl3) shows correlations between 13C NMR and 1H NMR peaks 
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Figure 33: HQSC two-dimensional NMR of AdSSPEG [5a] deuterated dimethylsulfoxide 
(DMSO) shows correlations between 13C NMR and 1H NMR peaks 
 
 HSQC two-dimensional NMRs in Figures 32 and 33 correspond to 
AdSSPEGOMe and AdSSPEG [5b, 5a], respectively. They both show strong 
correlations between the proton and carbon NMR peaks.  
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Figure 34: FTIR of AdSSPEGOMe [5b] 
 
Figure 35: FTIR of AdSSPEG [5a] 
 
 FTIR spectra in Figures 34 and 35 correspond to AdSSPEGOMe and 
AdSSPEG [5b, 5a], respectively. Here, we can see a clear difference between the 
two structures which confirms singular substitution was achieved on the hydroxyl 
terminated AdSSPEG [5a], as we can see a clear hydroxyl peak around 3300 cm-1 
in Figure 35, which is absent in Figure 34 with the methyl terminated 
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AdSSPEGOMe [5b], as expected. Typically, hydroxyl peaks on an FTIR spectra 
are broad but with AdSSPEG [5a] the peak is sharp. This is likely due to the other 
functional groups present in the polymer providing a shielding effect and 
decreasing the hydroxyl signal. Overall, both AdSSPEG and AdSSPEGOMe [5a, 
5b] were synthesized successfully and in good yield (69-74%). 
 Synthetically, the AdSSPEGOMe [5b] derivative is much easier to 
synthesize as di-substitution of the PEG molecule does not have to be considered. 
Final products AdSSPEG and AdSSPEGOMe [5a, 5b], although structurally very 
similar, exhibit much different behavior in aqueous solutions. Dialysis with the 
AdSSPEG [5a] derivative required ethanol addition as a co-solvent to get the guest 
molecule to go into solution, which was not necessary with the AdSSPEGOMe [5b] 
derivative as it was water soluble on its own. This is due to the hydroxyl versus 
methyl groups terminating the PEG chain. Here, the hydroxyl group pulls electron 
density away from the PEG chain, while the methyl group does not. This creates an 
overall stronger dipole moment for the methyl terminated guest than the hydroxyl 
terminated guest which explains the difference in water solubility.  
3.3 Synthesis of Thiol Modified Poly(ethylene-glycol) (PEG-diSH)   
 Thiol terminated linear PEG molecules (PEGdiSH) [7a-f] were synthesized 
according to Scheme 5 at various molecular weights (ie. 1000, 2000, 3400, 4000, 
10000, and 20000 g/mol), and characterized via 1H NMR to confirm that linear 
crosslinking molecules were synthesized as expected. 
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Scheme 4: Synthesis of [6] Poly(ethylene glycol)-di(p-toluenesulfonic acid) (PEGdiOTs), 
and [7] Poly(ethylene glycol)-dithiol (PEGdiSH) (n = 22 [7a], 45 [7b], 77 [7c], 227 [7e], 454 
[7f]) 
The ditosylation of PEG yielded excess unreacted TsCl that was very difficult to 
remove via aqueous workup. Instead, cellulose based filter paper was used to 
remove the excess TsCl. Here, the free hydroxyl groups in the cellulose structure 
are able to react with the excess TsCl when base is present to facilitate the 
substitution reaction in order to covalently bind the TsCl to the filter paper.76 
Therefore, the excess TsCl is able to be removed manually along with the filter 
paper. This method has proven to be extremely reliable and useful in obtaining a 
pure final product for use in the next synthetic step. The tosyl group provides a 
good leaving group for the nucleophilic SN2 double substitution reaction in the next 
step, where both sides of the PEG chain covalently bind to the thiol. Addition of 
base then creates urea as a side product as the final product of dithiolated PEG 
(PEGdiSH [7]) is formed.  
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Figure 36: 1H NMR of PEGdiSH (n = 90 [7d], 4000 g/mol) in deuterated chloroform 
(CDCl3) 
 
The proton NMR in Figure 36 corresponds to PEGdiSH (n = 90 [7d]). Proton NMRs 
for PEGdiSH (n = 22 [7a], 45 [7b], 77 [7c], 227 [7e], 454 [7f]) can be found in the 
appendix. Here, peaks labeled a correspond to the ethylene glycol protons in the 
repeat unit. It is likely that there are varying amounts of free unreacted PEG from 
the first step of this two-step synthesis, as the integrations are much more than 
would be expected for each of these polymers. However, NMR is not the most 
optimal way to characterize polymers, so it is also possible that electrostatic effects 
from the polymer chains are overlapping and hence interfering with the peak 
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intensities to cause the discrepancy in integration values. Peaks labeled b and c 
correspond to the protons bonded to the two carbons closest to the terminal thiol 
group on each side of the polymer. Peak c is slightly more upfield than peak b 
because the thiol group is more shielding than the oxygen group nearby. Peaks 
labeled d may correspond to the terminal thiol protons. These integrations are also 
not what we would expect because thiol protons, like hydroxyl protons, are known 
to have broad and unreliable peaks in 1H NMRs, if they show up at all. Additionally, 
peak d may also correspond to some type of grease, as this is also known to show 
up in the range of 1 ppm. Hence, the disappearance of tosyl proton peaks around 7-
8 ppm and the appearance of peak c at 2.8 ppm were used to confirm the formation 
of the final PEGdiSH [7] products. 
 PEGdiSH (n = 90 [7d], 227 [7e], and 454 [7f]) molecules are the purest 
comparatively, with only trace solvent peaks remaining from DMF and acetone. 
PEGdiSH (n = 22 [7a], 45 [7b], and 77 [7c]) had some other trace impurities 
present, but the molecules were deemed pure enough to use in subsequent reactions 
since these impurities had relatively small signals compared to the signals from the 
final product. Overall, PEGdiSH [7a-f] molecules were synthesized successfully. 
Yields from this synthetic pathway (27-48%) were not as high as we would 
typically like them to be for organic substitution reactions, but since all the starting 
materials are so inexpensive and widely available, the reactions did not need to be 
further optimized for our purposes.  
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3.4 Inclusion Complex Formation 
 Inclusion complexes were formed according to the method described in 
section 2.7, which is also demonstrated in Figure 37, by taking advantage of the 
hydrophobic effect through combining host and guest molecules in an aqueous 
environment. Here, the thioalkyl modified 𝛽CDs [2a, 2b] have very poor water 
solubility, so it is necessary to sonicate to help them go into solution so that host: 
guest inclusion complexes could be formed.  
Figure 37: Supramolecular amphiphile inclusion complex formation method with thioalkyl 
modified 𝛽CD [2a, 2b] host, and adamantyl-dithiopropionic acid modified PEG / 
PEGOMe [5a, 5b] guest. The hydrophobic effects drives inclusion when combining host 
and guest molecules in aqueous media, which affords a thin film inclusion complex to be 
used in future vesicle formation methods 
Four different host: guest combinations were made and tested- 𝛽CD-
C12:AdSSPEGOMe, 𝛽CD-C12:AdSSPEG, 𝛽CD-C14:AdSSPEGOMe, and 𝛽CD-
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C14:AdSSPEG. Here, C12 and C14 indicate the thioalkyl chain length attached to 
position 6 of the 𝛽CD. In this preparation method, sonication is an important step 
which helps bring the host and guest molecules into solution in order to drive 
inclusion complex formation. The process is repeated twice to give a higher 
probability that the inclusion complex will have formed. There are several methods 
commonly used to test for inclusion complex formation which often include 
examining the host and guest molecules on their own, a physical mixture of the host 
and guest molecules, and the inclusion complex. Among these are NMR, 
differential scanning calorimetry (DSC), and thermogravimetric analysis (TGA). 
NMR is not a particularly reliable method especially with non-ionic inclusion 
complexes, because it is likely that the chemical shifts will not show a distinct 
change with inclusion complexation. Here, the 𝛽CD inclusion complexes are not 
very water soluble, so obtaining comparable NMR data from hosts and guests on 
their own is also very difficult because the spectra appear broad and it is difficult 
to discern chemical shifts in peaks of interest. DSC and TGA measurements 
measure differences in phase transition and degradation temperatures, respectively. 
These methods are not useful in this case because we are not interested in these 
properties of our inclusion complexes, as they are designed to be used under 
physiological conditions, there is simply no need to test them at extreme conditions. 
Here, inclusion complex formation was confirmed through CMC testing with host 
and guest on their own compared to inclusion complexes, as described in sections 
2.10.2 and 3.5. This is because the CMC is an important parameter for amphiphilic 
self-assembly as it gives the minimum concentration required to form aggregates 
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with a particular supramolecular amphiphile in aqueous solutions. All four 
supramolecular amphiphile inclusion complexes efficaciously and consistently 
form, as further discussed in section 3.5. 
3.5 Critical Aggregation Concentration (CMC) via Fluorimetry 
 Nile red was chosen as a fluorescent probe for determining CMC because 
of its unique behavior in aqueous versus organic solutions. As demonstrated by 
Figure 38, nile red exhibits different emission wavelengths depending on whether 
it exists in a hydrophilic or a lipophilic environment.75  
Figure 38: Nile red emission spectra in aqueous environments (𝜆=?{kC\Ckn| =  515 nm, 𝜆=>kzzkn|  = 585 nm) compared to lipid environments (𝜆=?{kC\Ckn| = 554 nm, 𝜆=>kzzkn|  = 
638 nm) shows a notable shift in wavelength 
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The stokes shift, or the difference in energy between excitation and emission bands, 
is slightly larger for the lipophilic environment which makes it easier to detect with 
emission spectroscopy. Experimentally, a broad emission from approximately 530-
640 nm was observed for amphiphile concentrations below the CMC, while a sharp 
emission at 638 nm was observed at amphiphile concentrations above the CMC.  
 Nile red on its own is practically insoluble in water, so it tends to migrate 
to the air-water interface of aqueous solutions. When amphiphile is added to this 
solution, the nile red will be attracted to the hydrophobic moieties. As concentration 
of amphiphile is increased amphiphile will begin to self-assemble into a monolayer, 
and eventually a micelle due to the hydrophobic effect, as previously mentioned in 
section 1.3.2. Since the nile red is attracted to the hydrophobic moieties, it becomes 
encapsulated in the lipophilic interior of the micelle once formed, which then alters 
its fluorescence behavior. This process is summarized in Figure 39. 
 
 
 
 
 
 
 
 
 
97 
 
 
Figure 39: As amphiphile concentration is increased in aqueous solutions, amphiphilic 
molecules are driven to self-assemble into monolayers and eventually micelles due to the 
hydrophobic effect. Nile red becomes encapsulated in the lipophilic interior of the micelle 
as it is attracted to its hydrophobicity 
 Fluorescence spectroscopy was ran according to the method described in 
section 2.10.2 with each inclusion complex (ie. 𝛽CD-C12:AdSSPEGOMe, 𝛽CD-
C12:AdSSPEG, 𝛽CD-C14:AdSSPEGOMe, and 𝛽CD-C14:AdSSPEG), as well as 
the linear AdSSPEGOMe [5b] guest molecule on its own. The guest molecule was 
tested on its own to confirm that the inclusion complexes are forming unique 
supramolecular amphiphiles, and that we were not just observing the self-assembly 
of the guest molecule. Macrocyclic 𝛽CD-C12 [2a] and 𝛽CD-C14 [2b] hosts were 
not tested on their own due to their poor water solubility. Because of this, it is highly 
impractical that they would self-assemble on their own. Overall, this method 
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yielded consistent results, and for each sample there was a note-able difference in 𝜆=> maximum before and after the CMC, which was as expected since nile red 
emits at higher wavelengths in lipophilic environments, such as the interior of a 
micelle. Raw data in Figure 40 demonstrates this difference for one sample before 
and after the CMC. 
 
 
Figure 40: Fluorescence emission spectrum of supramolecular amphiphile 
AdSSPEGOMe:𝛽CD-C12 before the CMC at 585 nm (left) and after the CMC at 638 nm 
(right). Initial excitation at 515 nm before the CMC (left) is not shown because wavelengths 
were only monitored in the range of 530 – 670 nm. Excitation was at 554 nm after the CMC 
(right) 
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Figure 41: AdSSPEGOMe [5b] linear guest molecule CMC measured via fluorescence 
emission spectroscopy at approximately 638 nm and various concentrations of amphiphile 
and nile red held constant at 0.156 𝜇g/mL. CMC was found to be 200.54 𝜇M 
 
Figure 42: AdSSPEGOMe:𝛽CD-C12 inclusion complex CMC measured via fluorescence 
emission spectroscopy at approximately 638 nm and various concentrations of amphiphile 
and nile red held constant at 0.156 𝜇g/mL. CMC was found to be 30.50	𝜇M 
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Figure 43: AdSSPEGOMe:𝛽CD-C14 inclusion complex CMC measured via fluorescence 
emission spectroscopy at approximately 638 nm and various concentrations of amphiphile 
and nile red held constant at 0.156 𝜇g/mL. CMC was found to be 27.16 𝜇M 
Figure 44: AdSSPEG:𝛽CD-C12 inclusion complex CMC measured via fluorescence 
emission spectroscopy at approximately 638 nm and various concentrations of amphiphile 
and nile red held constant at 0.156 𝜇g/mL. CMC was found to be 37.85 𝜇M 
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Figure 45: AdSSPEG:𝛽CD-C14 inclusion complex CMC measured via fluorescence 
emission spectroscopy at approximately 638 nm and various concentrations of amphiphile 
and nile red held constant at 0.156 𝜇g/mL. CMC was found to be 35.97 𝜇M 
 
Table 2: CMC results for all inclusion complexes and AdSSPEGOMe guest molecule on 
its own confirm inclusion complex formation, and give the minimum aggregation 
concentrations required for self-assembly 
 
 
 
 
 
 
 Figures 41-45 and Table 2 summarize these results. For each sample, we 
see a stark difference in slope before and after the CMC, which was as expected. 
Here, the AdSSPEGOMe [5b] guest molecule (Figure 41) was shown to exhibit a 
CMC at more than five times that of all the inclusion complexes (Figures 42-45), 
Sample CMC (𝝁M) 
AdSSPEGOMe1000:𝜷CD-C12 30.50 
AdSSPEGOMe1000:	𝜷CD-C14 27.16 
AdSSPEG1000:	𝜷CD-C12 37.85 
AdSSPEG1000:	𝜷CD-C14 35.97 
AdSSPEGOMe1000 200.54 
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as it is more soluble in water on its own than it is when it is included in the thioalkyl 
modified 𝛽CD host. Additionally, thioalkyl 𝛽CD inclusion complexes with longer 
alkyl chains (ie. C14) have lower CMCs, which is also consistent with the principles 
of the hydrophobic effect and micellization; longer alkyl chains are less soluble in 
aqueous solutions and therefore tend to aggregate at lower concentrations than 
molecules with shorter alkyl chains. Similarly, AdSSPEG [5a] inclusion complexes 
have slightly higher CMCs than AdSSPEGOMe [5b] inclusion complexes, which 
could be due to the terminal hydroxyl group of AdSSPEG [5a] having more 
hydrogen bonding ability than the methyl ether group and hence increasing water 
solubility. These results were useful for subsequent vesicle formation reactions as 
the minimum aggregation concentration was increased to form vesicles, and the 
minimum amount of materials was used. 
3.6 Vesicle Formation 
 Vesicles were formed according to the method described in section 2.8, 
which is also demonstrated in Figure 46. Here, thin film inclusion complexes, as 
demonstrated by Figure 47, are suitable for rehydration to form vesicles via this 
method.  
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Figure 46: Thin film inclusion complex with thioalkyl modified 𝛽CD [2a, 2b] host, and 
adamantyl-dithiopropionic acid modified PEG / PEGOMe [5a, 5b] guest is rehydrated with 
Tris buffer and subjected to five freeze-thaw cycles to afford vesicles. The solution is probe 
sonicated to break up any larger aggregates, filtered, and extruded to obtain pure 
monodisperse vesicles 
 
Figure 47: Inclusion complexes βCD-C12:AdSSPEG (left), and βCD-
C14:AdSSPEGOMe (right) form thin films in round bottom flasks that are suitable for 
rehydration to form vesicles 
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Four different inclusion complexes were used to make vesicles- 𝛽CD-
C12:AdSSPEGOMe, 𝛽CD-C12:AdSSPEG, 𝛽CD-C14:AdSSPEGOMe, and 𝛽CD-
C14:AdSSPEG. Controls with AdSSPEGOMe [5b], AdSSPEG [5a], 𝛽CD-C12 
[2a], and 𝛽CD-C14 [2b] on their own were also tested to further confirm that only 
the inclusion complexes self-assemble to bilayered vesicles. Freeze-thaw cycles 
“shock” the supramolecular amphiphiles and helps drive their self-assembly, while 
probe sonication breaks up larger aggregates that may have formed during this 
process. Filtering removes these larger particles, and extrusion further purifies the 
vesicle solution to obtain a more monodisperse sample. Probe sonication and 
extrusion methods were used to together as this method yielded the most consistent 
and stable vesicles as compared to just extrusion or just probe sonication as an 
isolation method, which will be further discussed in section 3.9. Vesicle solutions 
in Tris buffer were made at pH 7.4 and 8.5. 
 For this project we did not have access to high resolution microscopy such 
as SEM to confirm vesicle formation, so in order to confirm that vesicles were 
forming as expected, we encapsulated a fluorescent dye in the vesicle interior and 
destroyed them, as described in section 2.10.1 and discussed in section 3.8, and 
measured their particle size using dynamic light scattering to see if they were 
consistent with literature references, as described in section 2.11.1 and discussed in 
section 3.9. Overall, none of the control samples formed vesicles. All inclusion 
complexes formed vesicles consistently, and their particle sizes were consistent 
with literature values (100-250 nm diameter),61-74 and were stable for several weeks 
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up to approximately one month before degradation and/or aggregating into larger 
particles.  
3.7 Fluorescent Vesicle Formation 
 Fluorescent vesicles were formed according to the method described in 
section 2.9, which is also demonstrated in Figure 48.  
 
Figure 48: Thin film inclusion complex with thioalkyl modified βCD [2a, 2b] host, and 
adamantyl-dithiopropionic acid modified PEG / PEGOMe [5a, 5b] guest is rehydrated with 
CF buffer and subjected to five freeze thaw cycles to afford vesicles. The solution is probe 
sonicated to break up any larger aggregates, filtered, and extruded. The resulting vesicle 
containing solution is further purified with a sephadex G-50 column to obtain pure 
monodisperse vesicles with encapsulated CF 
 
Four different inclusion complexes were used to make fluorescent vesicles- 𝛽CD-
C12:AdSSPEGOMe, 𝛽CD-C12:AdSSPEG, 𝛽CD-C14:AdSSPEGOMe, and 𝛽CD-
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C14:AdSSPEG. Controls with AdSSPEGOMe, AdSSPEG, 𝛽CD-C12, and 𝛽CD-
C14 on their own were also tested to further confirm that only the inclusion 
complexes self-assemble to bilayered vesicles. This method is similar to the 
previously discussed vesicle formation method in section 3.6, with the modification 
of a fluorescently labeled CF buffer, and a sephadex G-50 column to remove free 
CF that was not encapsulated in the vesicle interior and any smaller aggregates that 
may have survived extrusion. 
This sephadex G-50 column is a size exclusion chromatography method 
which elutes larger particles first as they are not absorbed into the porous medium 
like smaller particles are. This method allows for the isolation of pure monodisperse 
vesicles with encapsulated fluorescent CF, as demonstrated by Figure 49. By 
encapsulating a fluorescent small molecule during vesicle formation, we were able 
to determine if vesicles are forming as expected, and if they are capable of 
encapsulating small molecules. These parameters are tested via methods described 
in section 2.10.1 and discussed in section 3.8. Overall, all inclusion complexes 
formed vesicles and encapsulated the small molecule CF consistently, while 
controls did not show any signs of vesicle formation or subsequent encapsulation 
of CF. 
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Figure 49: Sephadex G-50 column (left) elutes free CF, vesicles, and then smaller 
aggregates such as micelles. Fractions 1-3 (right) are bright yellow, orange, and brown 
(left-right) where the bright yellow fraction contains free CF, the orange fraction contains 
vesicles, and the brown fraction contains smaller aggregates 
3.8 Fluorescent Vesicle Encapsulation and Lysing via Fluorimetry 
 Fluorescent vesicles and controls were prepared according to the methods 
described in section 2.9, and discussed in section 3.7. Fluorescence spectroscopy 
was ran according to the methods described in section 2.10.1 to probe the behavior 
of the vesicles to see if they formed and encapsulated fluorescent probe CF as 
expected. This method relies on the principles of the quenching of fluorescence, 
which is a process in which a fluorophore comes into contact with a quencher by 
either a static or dynamic mechanism to effectively decrease the fluorescence 
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intensity of a sample.77 In the case of CF, it acts as both the fluorophore and the 
quencher through a static mechanism as it forms non-fluorescent dimers with itself 
at high concentrations.78 For these experiments, CF was encapsulated in the interior 
of supramolecular vesicles at a concentration of 50 mM, which is well above the 
self-quenching concentration.78 Therefore, when encapsulated in the vesicles, CF 
is non-fluorescent. When the vesicles are lysed, encapsulated CF is released to the 
surrounding environment and substantially diluted with regain of fluorescence.  
 This process was monitored via fluorescence spectroscopy with diluted 
vesicle samples, so if vesicles formed and encapsulated CF a large change in the 
fluorescence intensity is observed when lysed with 10% Triton X-100 detergent. If 
vesicles did not form, a small change in fluorescence intensity is observed when 
lysed with 10% Triton X-100 as a result of the dilution of any free CF already in 
solution, or the breaking up of other aggregates that may contain small amounts of 
CF. As demonstrated by Figure 50, all inclusion complex samples demonstrate a 
large increase in fluorescence compared to controls (ie. host and guest molecules 
on their own).  
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Figure 50: Initial vesicle lysing %∆Fluorescence Intensity (left) of inclusion complexes βCD-C12:AdSSPEGOMe, βCD-C12:AdSSPEG, βCD-C14:AdSSPEGOMe, and βCD-
C14:AdSSPEG and controls AdSSPEGOMe, AdSSPEG, βCD-C12, and βCD-C14 shows 
a much higher average %∆Fluorescence Intensity for inclusion complex samples (ie. 
vesicles) than it does for controls (ie. host and guest molecules on their own), which 
indicates vesicle formation and CF encapsulation for inclusion complexes, while controls 
do not form vesicles or encapsulate CF. Two-week vesicle lysing %∆Fluorescence 
Intensity (right) shows the same average %∆Fluorescence Intensity for inclusion complex 
samples (ie. lysed vesicles) and controls, which indicates that the vesicles formed from 
inclusion complex samples have self-degraded 
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Figure 51: AdSSPEGOMe:𝛽CD-C12 inclusion complex formed vesicles with encapsulated 
CF. When lysed with 250 𝜇L 10% Triton X-100 there is a large increase in fluorescence 
intensity because CF is released and diluted below the self-quenching concentration range 
 
These unique properties of the host and guest molecules confirm that the 
supramolecular amphiphiles are formed, self-assemble into vesicles, and 
encapsulate CF, while controls do not form vesicles on their own. All samples were 
measured over time to monitor self-degradation behavior, and it was found that the 
vesicles degraded on their own after approximately two weeks, as evident by the 
uniform increase in fluorescence compared to controls. All measurements used to 
calculate average values shown in Figure 50 are listed in Table 3, and a sample raw 
fluorescence measurement is demonstrated by Figure 51 (all other fluorescence 
measurements can be found in the appendix). 
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 Table 3: % ∆Fluorescence Intensity of vesicle forming inclusion complexes with 
encapsulated CF, and controls when lysed with 250	𝜇L 10% Triton X-100 over time. After 
two weeks, the vesicles with encapsulated CF have degraded, which is evident by the 
decrease in % ∆Fluorescence Intensity compared to previous measurements 
 
 
3.9 Vesicle Particle Size via DLS 
 Samples that were demonstrated to form vesicles, as discussed in section 
3.8, (ie. inclusion complexes βCD-C12:AdSSPEGOMe, βCD-C12:AdSSPEG, βCD-C14:AdSSPEGOMe, and βCD-C14:AdSSPEG) were prepared via the 
Time Sample % ∆Fluorescence Intensity 
Initial 
AdSSPEG1000 328.57 𝛽CD-C12 209.52 𝛽CD-C14 369.70 
AdSSPEGOMe1000 96.08 
AdSSPEG1000:	𝛽CD-C12 2071.43 
AdSSPEG1000:	𝛽CD-C14 1768.42 
AdSSPEG1000OMe:	𝛽CD-C12 2203.03 
AdSSPEG1000OMe:	𝛽CD-C14 1875.00 
1 week 
AdSSPEG1000 254.17 𝛽CD-C12 150.88 𝛽CD-C14 272.55 
AdSSPEGOMe1000 135.29 
AdSSPEG1000:	𝛽CD-C12 2070.00 
AdSSPEG1000:	𝛽CD-C14 1548.15 
AdSSPEG1000OMe:	𝛽CD-C12 2185.71 
AdSSPEG1000OMe:	𝛽CD-C14 1821.05 
2 week 
AdSSPEG1000 409.68 𝛽CD-C12 267.65 𝛽CD-C14 248.57 
AdSSPEGOMe1000 110.00 
AdSSPEG1000:	𝛽CD-C12 156.41 
AdSSPEG1000:	𝛽CD-C14 156.76 
AdSSPEG1000OMe:	𝛽CD-C12 408.57 
AdSSPEG1000OMe:	𝛽CD-C14 175.00 
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method described in section 2.8, and initially discussed in section 3.6, for 
measuring particle size via DLS.  
 
Table 4: Particle size of vesicle samples comparing isolation methods of probe sonication 
and extrusion, wherein extrusion yields more consistent hydrodynamic radii and lowers 
polydispersity 
*of the highest intensity peak 
 
As demonstrated by data in Table 4, when comparing vesicle isolation methods of 
probe sonication and extrusion, extrusion yields much more consistent 
hydrodynamic radii of vesicles (which are consistent with previously mentioned 
literature values in section 3.6) with lower polydispersity than probe sonication. 
Both of these characteristics are highly desirable for vesicle nanocarriers as their 
behavior is more predictable and consistent.  
 All vesicle containing samples isolated via extrusion were monitored over 
the course of ten weeks to determine a time range of when degradation and/or 
Sample Isolation Method 
# of 
peaks 
Hydrodynamic 
Radius (nm)* %Intensity* %PD* 
AdSSPEG1000:	𝛃CD-C12 Probe Sonication 3 107.13 90.4 58.9 
Extruder 2 64.36 98.7 32.3 
AdSSPEG1000:	𝛃CD-C14 Probe Sonication 3 97.53 71.7 52.4 
Extruder 3 64.34 94.5 28.2 
AdSSPEGOMe1000:	𝛃CD-
C12 
Probe 
Sonication 3 128.43 92.6 98.3 
Extruder 2 64.12 93.1 32.4 
AdSSPEGOMe1000:	𝛃CD-
C14 
Probe 
Sonication 3 94.23 92.3 23.6 
Extruder 2 48.21 93.4 21.2 
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further aggregation into much larger particles occurs for vesicles without any 
encapsulated payloads. It was previously established that vesicles with 
encapsulated CF have a shelf life of approximately two weeks. Here, vesicles 
without any encapsulated agent have a shelf life of approximately 3 to 5 weeks. 
Interestingly, the particle size distribution of these vesicles became more uniform 
over time before degradation/further aggregation occurred, as demonstrated by 
Figures 52 and 53. This is likely due to a more stable thermodynamic equilibrium 
being established over time after vesicle formation. 
 
 
Figure 52: Initial  % Intensity v. Hydrodynamic Radius (nm) of vesicle samples derived 
from inclusion complexes 𝛽CD-C12:AdSSPEGOMe, 𝛽CD-C12:AdSSPEG, 𝛽CD-
C14:AdSSPEGOMe, and 𝛽CD-C14:AdSSPEG demonstrates uniform radii with low 
polydispersity. Note that the legend C12 indicates 𝛽CD-C12 and C14 indicates  𝛽CD-C14 
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Figure 53: 1 week  % Intensity v. Hydrodynamic Radius (nm) of vesicle samples derived 
from inclusion complexes 𝛽CD-C12:AdSSPEGOMe, 𝛽CD-C12:AdSSPEG, 𝛽CD-
C14:AdSSPEGOMe, and 𝛽CD-C14:AdSSPEG demonstrates even more uniform radii with 
lower polydispersity than initial measurements. Note that the legend C12 indicates 𝛽CD-
C12 and C14 indicates  𝛽CD-C14 
3.10 Vesicle Glutathione (GSH) Degradation via DLS 
 Samples that were demonstrated to form vesicles, as discussed in section 
3.8 and 3.9, (ie. inclusion complexes βCD-C12:AdSSPEGOMe, βCD-
C12:AdSSPEG, βCD-C14:AdSSPEGOMe, and βCD-C14:AdSSPEG) were 
prepared via the method described in section 2.8 for measuring vesicle degradation 
in the presence of both intracellular and extracellular glutathione (GSH), as well as 
10% Triton X-100 via DLS. As previously mentioned in section 1.4.1, GSH is a 
naturally occurring antioxidant found at higher concentrations inside cells than 
outside. The thiol group in GSH degrades the vesicles through a dynamic disulfide 
exchange reaction with the disulfide group embedded in the linear guest molecule 
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of the vesicles’ bilayer membrane. This reaction will alter the HLB of the vesicles’ 
bilayer membrane and cause it to degrade and release any encapsulated payload due 
to the degree of polarity and small size of GSH. Hence, GSH was used to mimic 
these physiological conditions in vitro. Here, it is desirable for vesicles to degrade 
under intracellular concentrations of GSH but remain intact under extracellular 
conditions. These experiments were ran according to the method described in 
section 2.11.2 with 12 mM GSH to mimic the intracellular environment, and 20 𝜇M GSH to mimic the extracellular environment. Initial vesicle particle size 
distributions for these experiments is shown in Figure 53. An aliquot from each 
vesicle sample 1 week after formation was incubated overnight in both intra and 
extracellular GSH and particle size distribution was measured the next day.  
 When comparing initial vesicle particle size measurements with vesicle 
particle size in 10% Triton X-100 containing environments, all vesicle samples 
were reduced to a hydrodynamic radius of approximately 5 nm. This indicates that 
all aggregates have been broken up, and is consistent with fluorescent vesicle lysing 
results that demonstrate this detergent’s ability to lyse vesicles.  
 When comparing initial vesicle particle size measurements with vesicle 
particle size in GSH containing environments, it can be concluded that there is 
much more of a chemical change with the intracellular GSH containing samples 
than with the extracellular GSH containing samples. Here, it is evident that the 
polydispersity and particle size of the intracellular GSH containing samples 
changed dramatically, while the extracellular GSH containing samples still 
demonstrate hydrodynamic radii within the expected range for all samples. This 
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could indicate that vesicles are more stable in extracellular environments than 
intracellular environments, which is ideal for drug delivery systems as it is desirable 
for the drug to be released from the vesicle nanocarrier intracellularly and remain 
stable extracellularly. Figures 54 and 55 demonstrate this difference in particle size 
distribution of vesicles between intracellular and extracellular environments, 
respectively, while Figures 56 and 57 demonstrate direct comparisons of vesicle 
samples before and after GSH incubation.  
 
 
Figure 54: 12 mM GSH, pH 8.5, reaction time overnight  % Intensity v. Hydrodynamic 
Radius (nm) of vesicle samples derived from inclusion complexes 𝛽CD-
C12:AdSSPEGOMe, 𝛽CD-C12:AdSSPEG, 𝛽CD-C14:AdSSPEGOMe, and 𝛽CD-
C14:AdSSPEG demonstrates an dramatic increase in polydispersity and a change in overall 
particle size, which may indicate vesicle degradation in intracellular environments. Note 
that the legend C12 indicates 𝛽CD-C12 and C14 indicates  𝛽CD-C14 
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Figure 55: 20 µM GSH, pH 8.5, reaction time overnight  % Intensity v. Hydrodynamic 
Radius (nm) of vesicle samples derived from inclusion complexes βCD-
C12:AdSSPEGOMe, βCD-C12:AdSSPEG, βCD-C14:AdSSPEGOMe, and βCD-
C14:AdSSPEG demonstrates a slight increase in polydispersity, but no change in overall 
particle size, which may indicate vesicle stability in extracellular environments. Note that 
the legend C12 indicates βCD-C12 and C14 indicates  βCD-C14 
 
For intracellular GSH containing samples, new peaks at less than 1 nm and greater 
than 1000 nm in radii are observed. This could indicate that the vesicles are either 
being broken down into smaller aggregates such as micelles or the individual 
inclusion complex building blocks (ie. less than 1 nm), or are forming even larger 
aggregates (ie. greater than 1000 nm) once the highly ordered vesicle structure is 
destroyed by intracellular GSH. This is because, contrary to 10% Triton X-100, 
GSH will only disrupt vesicles, while the detergent disrupts all aggregates.  
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Figure 56: 12 mM GSH, pH 8.5, reaction time overnight compared to initial  % Intensity 
v. Hydrodynamic Radius (nm) of vesicle samples derived from inclusion complex 𝛽CD-
C12:AdSSPEGOMe demonstrate a dramatic increase in polydispersity and a very wide 
broadening of overall particle size distribution, which may indicate vesicle degradation in 
intracellular environments. Note that the legend C12 indicates 𝛽CD-C12  
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Figure 57: 20 𝜇M GSH, pH 8.5, reaction time overnight compared to initial  % Intensity 
v. Hydrodynamic Radius (nm) of vesicle samples derived from inclusion complex 𝛽CD-
C14:AdSSPEGOMe demonstrate an increase in polydispersity and a slight broadening of 
overall particle size distribution, which may indicate vesicle stability in extracellular 
environments. Note that the legend C14 indicates  𝛽CD-C14 
 
 It is important to note that these experiments only indicate whether or not a 
reaction is happening with GSH in extracellular and intracellular environments, and 
does not definitively confirm, but rather may indicate, whether or not vesicles are 
degrading. This is because DLS only measures hydrodynamic radius, which is by 
definition dynamic, and may change as a result of external environment with or 
without vesicle degradation. Dialysis experiments that measure the concentration 
of encapsulated payload release over time are currently underway to determine 
definitively if vesicles are degrading in extracellular or intracellular environments 
or not, as well as the rate of release of encapsulated drugs. 
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3.11 Hydrogel Formation 
 Hydrogel formation was attempted with each vesicle sample that was 
demonstrated to form vesicles, as discussed in section 3.8-3.10, (ie. inclusion 
complexes βCD-C12:AdSSPEGOMe, βCD-C12:AdSSPEG, βCD-
C14:AdSSPEGOMe, and βCD-C14:AdSSPEG). As previously mentioned in 
section 1.5.1, it is desirable to combine vesicle and hydrogel drug delivery 
platforms to mitigate their individual drawbacks (ie. burst release of encapsulated 
drug with hydrogels, and poor stability of vesicles), and create an optimized hybrid 
drug delivery system. Here, vesicles were prepared via the method described in 
section 2.8, and hydrogel gelation reactions were attempted via the method 
described in section 2.12. Although a variety of pHs (7.4, 8.5), temperatures (25, 
30, 35, 40, 45, 50, 55 ℃), and amounts of PEGdiSH [7a-f] and vesicles were tested, 
all samples demonstrated liquid flow behavior and were not able to hold their own 
weight, which is not consistent with hydrogel formation. Samples with PEGdiSH 
[7e, 7f] molecular weight of 10000 or 20000 g/mol demonstrated a visual increase 
in viscosity at pH 8.5 and all temperatures and  ≥ 10 wt/wt% PEGdiSH, which 
indicates that a reaction is occurring.  
 In theory, the disulfide exchange between the thiol group in the hydrophilic 
crosslinker (PEGdiSH) and the disulfide group in the vesicles should not lyse the 
vesicles, as the exterior HLB is maintained with a hydrophilic crosslinker. This 
theory was confirmed via DLS particle size measurements (ran according to the 
method described in section 2.11.1) with the PEGdiSH [7e] containing vesicle 
solutions (20 wt/wt% PEGdiSH calculated according to Equation 4, pH 8.5, 
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reaction time 1 hr at room temperature). Particle size distribution demonstrated by 
Figures 58 indicate that the vesicles are stable with crosslinker addition, as the 
particle size was only slightly increased, and polydispersity was shown to be 
unchanged compared to initial measurements demonstrated by Figure 53. Figure 
59 shows a direct comparison between a neat vesicle sample, and a PEGdiSH 
containing vesicle sample which confirm the aforementioned observations. 
Additionally, it is evident that a reaction is occurring and eliciting a chemical 
change in the solution by the slight increase in particle size, but this reaction was 
not enough to crosslink the vesicles into a hydrogel. 
 
Figure 58: 20 wt/wt% PEGdiSH [7e], pH 8.5, reaction time 1 hour 	% Intensity v. 
Hydrodynamic Radius (nm) of vesicle samples derived from inclusion complexes 𝛽CD-
C12:AdSSPEGOMe, 𝛽CD-C12:AdSSPEG, 𝛽CD-C14:AdSSPEGOMe, and 𝛽CD-
C14:AdSSPEG demonstrates no change in polydispersity, and a slight increase in overall 
particle size, which may indicate vesicle stability with a hydrophilic crosslinker. Note that 
the legend C12 indicates 𝛽CD-C12 and C14 indicates  𝛽CD-C14, and PEGdiSH10k 
indicates [7e] 
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Figure 59: 20 wt/wt% PEGdiSH [7e], pH 8.5, reaction time 1 hour 	% Intensity v. 
Hydrodynamic Radius (nm) of vesicle samples derived from inclusion complexes 𝛽CD-
C12:AdSSPEGOMe demonstrates no change in polydispersity, and a slight increase in 
overall particle size, which may indicate vesicle stability with a hydrophilic crosslinker. 
Note that the legend C12 indicates 𝛽CD-C12 and PEGdiSH10k indicates [7e] 
 Results from previous experiments testing vesicle stability in intracellular 
and extracellular GSH environments (discussed in section 3.10) indicate that the 
disulfide bond embedded in the exterior of the vesicle membrane is indeed 
accessible, as some vesicle degradation was indicated in intracellular GSH 
environments. Hence, it can be further confirmed that a reaction is happening, but 
that the overall crosslinking density is not enough to form a hydrogel. Future 
experiments with multi-arm PEGdiSH crosslinkers would likely increase the 
crosslinking density enough to form a hydrogel.  
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4. CONCLUSION 
In summary, thioalkyl modified 𝛽CD-C12 [2a] and 𝛽CD-C14 [2b] were 
successfully synthesized as macrocyclic hosts for novel AdSSPEGOMe [5b] and 
AdSSPEG [5a] linear guest molecules. All host and guest combinations were 
demonstrated to form inclusion complexes with critical aggregation concentrations 
in the range of 30-40 𝜇M. These inclusion complexes were used to form bilayered 
vesicles with hydrodynamic diameters ranging from 100-150 nm and were stable 
for over a month. This shelf life is much longer than is typical of phospholipid 
based liposomes of this nature, which indicates enhanced stability from this novel 
host: guest combination. All vesicles were also able to encapsulate a small organic 
molecule within their core during vesicle formation, with triggered release in the 
presence of detergent. Vesicles with a disulfide bond covalent embedded in the 
bilayer membrane were shown to be more sensitive to intracellular concentrations 
of GSH than extracellular through a dynamic disulfide exchange reaction, which 
could serve as a stimuli induced release mechanism for encapsulated payloads once 
vesicles are taken up into cells. 
Linear PEGdiSH [7a-f] of varying molecular weights from 1000-20000 
g/mol were also successfully synthesized as crosslinking molecules to link the 
three-dimensional vesicles as multivalent junctions and form a hydrogel coating. 
However, although a variety of pHs, temperatures, and ratios of SH/SS were tested, 
hydrogels did not form under any conditions. A visual increase in viscosity was 
observed with crosslinkers with molecular weights ≥ 10000 g/mol, so there was 
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evidence that a reaction was occurring. It can be concluded that the crosslinking 
density with the linear crosslinkers was not enough to form a hydrogel. 
Overall, vesicles formed from this novel host: guest combination are 
extremely promising for achieving a hybrid vesicle-hydrogel drug delivery system 
that can be applied as a coating or injected directly to a target site. The 
biocompatibility, stimuli responsivity, enhanced stability, and ease of preparation 
and modification of these materials is highly desirable for this purpose. Future work 
is needed to bring this novel drug delivery system from in vitro studies to in vivo 
studies for commercial applicability.   
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5. FUTURE WORK 
Future work on this project should include more quantitative release studies 
with all vesicle samples. These studies should include the use of a model drug 
molecule such as curcumin, 𝛼-tocopherol, or doxorubicin. Vesicles with 
encapsulated drug payload should be isolated so that there is no free drug in 
solution, and then treated with both extracellular and intracellular concentrations of 
GSH to monitor % Drug Release over time. This method will give information on 
the kinetic release rates from these novel vesicles, as well as drug loading capacity 
and more quantitative measurements of degradation in the presence of GSH.  
Additionally, hydrogel formation studies with a multi-arm thiol terminated 
PEG with molecular weight ≥ 10000 g/mol in order to increase the crosslinking 
density enough to form a hydrogel should be performed. A 4-arm thiol terminated 
PEG with a pentraethythritol core structure, as shown in Figure 60, would be a 
suitable material for this purpose. 
 
Figure 60: Condensed (left) and expanded (left) chemical structures of 4-arm thiol terminated 
PEG 
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Once hydrogels are formed, they should be characterized for mechanical and 
rheological properties, as well as swelling behavior and adhesion to various 
materials commonly used in medical devices. The crosslinking molecule should 
then be modified with an acid labile siyl-ether bond in its core structure to embed 
an acid sensitive degradation mechanism. Hydrogels, similarly to the vesicles, 
should also be studied for the encapsulation and release of model drugs with 
environments of varying acidity to probe the triggered degradation, drug loading 
capacity, and release rates of the material.  
It may also be of interest to modify the host and guest molecules with 
varying functionalities to probe their behavior for other drug delivery related 
applications. All suggestions for future work are summarized in Figure 61. 
Additionally, once all future work pathways described in Figure 61 have 
been explored, this material should undergo additional multidisciplinary 
characterizations by biologists and/or biomedical engineers to determine the 
viability of this novel drug delivery system for commercial applications as 
antibacterial coatings. Among others, these studies should include in vitro cell 
viability and drug delivery tests under physiological conditions, as well as broad 
spectrum bactericidal studies with encapsulated antibiotics to determine their safety 
in the presence of healthy eukaryotic cells versus bacteria-infected cells, as well as 
their effectiveness against a variety of different types of bacteria, respectively. Once 
in vitro studies have been thoroughly explored and the material has been further 
optimized to demonstrate viability, in vivo studies should be conducted according 
to FDA standards.   
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Figure 61: Summary of future work includes a) functionalization of vesicles b) crosslinking to 
form a hydrogel with thiol terminated 4-arm PEG with a siyl-ether core structure c) acid 
triggered degradation and release of hydrogel encapsulated payload and d) GSH triggered 
degradation and release of vesicle encapsulated payload  
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APPENDICES 
A. Supporting Information 
 
 
Figure 1A: 1H NMR of PEGdiSH (n = 22 [7a], 1000 g/mol) in deuterated chloroform (CDCl3)  
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Figure 2A: 1H NMR of PEGdiSH (n = 45 [7b], 2000 g/mol) in deuterated chloroform (CDCl3)  
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Figure 3A: 1H NMR of PEGdiSH (n = 77 [7c], 3400 g/mol) in deuterated chloroform (CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Note- 1H NMR for PEGdiSH (n = 90 [7d], 4000 g/mol) can be found on page 89  
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Figure 4A: 1H NMR of PEGdiSH (n = 227 [7e], 10000 g/mol) in deuterated chloroform (CDCl3) 
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Figure 5A: 1H NMR of PEGdiSH (n = 454 [7f], 20000 g/mol) in deuterated chloroform (CDCl3) 
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Table 1A: AdSSPEGOMe fluorescence measurements with varying concentration of amphiphile 
and 0.156 𝜇𝑔/𝑚𝐿 nile red 
  
[Amphiphile] 
(µM) Trial # 𝝀𝒆𝒎	𝒎𝒂𝒙 (nm) Intensity (CPS) Avg 𝝀𝒆𝒎	𝒎𝒂𝒙 (nm) Avg Intensity (CPS) 
60 
1 618 1916830 
618 1867717 2 617 1833120 
3 619 1853200 
80 
1 616 2497720 
617 2284580 2 618 1919240 
3 616 2436780 
100 
1 611 2622970 
613 2563893 2 616 2487530 
3 612 2581180 
120 
1 605 3231220 
609 3137913 2 611 3078210 
3 611 3104310 
140 
1 613 3280050 
611 3257833 2 611 3274040 
3 610 3219410 
160 
1 608 3538580 
608 3514243 2 608 3516570 
3 609 3487580 
180 
1 606 3769400 
606 3625443 2 609 3513960 
3 603 3592970 
200 
1 606 3879300 
609 3904533 2 609 3938560 
3 612 3895740 
300 
1 611 3756220 
612 3676017 2 612 3667560 
3 612 3604270 
400 
1 610 3899340 
611 3892133 2 611 3866450 
3 611 3910610 
500 
1 613 4212220 
612 4203663 2 612 4196020 
3 612 4202750 
144 
 
Table 2A: AdSSPEG:𝛽CD-C12 fluorescence measurements with varying concentration of 
amphiphile and 0.156 𝜇𝑔/𝑚𝐿 nile red 
 
 
  
 
 
[Amphiphile] 
(𝝁𝑴) Trial # 𝝀𝒆𝒎	𝒎𝒂𝒙 (nm) Intensity (CPS) Avg 𝝀𝒆𝒎	𝒎𝒂𝒙 (nm) Avg Intensity (CPS) 
20 
1 589 2692380 
585 2537227 2 583 2495070 
3 582 2424230 
25 
1 592 3132520 
589 3151507 2 588 3195730 
3 586 3126270 
30 
1 592 3365420 
588 3347943 2 585 3353890 
3 588 3324520 
35 
1 596 3471490 
597 3436180 2 598 3433940 
3 597 3403110 
40 
1 605 3802830 
608 3848590 2 608 3885400 
3 610 3857540 
45 
1 594 3928990 
595 3950447 2 592 3978470 
3 598 3943880 
50 
1 620 4194430 
623 4194377 2 623 4192320 
3 625 4196380 
55 
1 623 4196350 
625 4198460 2 623 4199820 
3 630 4199210 
60 
1 622 4203100 
625 4198200 2 627 4195670 
3 625 4195830 
80 
1 629 4191630 
629 4195527 2 629 4196600 
3 628 4198350 
100 
1 632 4196930 
634 4196643 2 635 4195210 
3 636 4197790 
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Table 3A: AdSSPEG:𝛽CD-C14 fluorescence measurements with varying concentration of 
amphiphile and 0.156 𝜇𝑔/𝑚𝐿 nile red 
 
 
[Amphiphile] 
(𝝁𝑴) Trial # 𝝀𝒆𝒎	𝒎𝒂𝒙 (nm) Intensity (CPS) Avg 𝝀𝒆𝒎	𝒎𝒂𝒙 (nm) Avg Intensity (CPS) 
15 
1 596 1773950 
596 1810597 2 599 1816450 
3 594 1841390 
20 
1 599 2330300 
594 2290830 2 598 2314230 
3 585 2227960 
25 
1 600 2683510 
598 2587940 2 595 2538300 
3 600 2542010 
30 
1 606 2673540 
607 2669550 2 609 2650390 
3 607 2684720 
35 
1 610 3187780 
611 3093063 2 614 3049850 
3 609 3041560 
40 
1 611 3219960 
615 3266520 2 619 3371220 
3 615 3208380 
45 
1 626 3454260 
628 3453957 2 628 3457990 
3 630 3449620 
50 
1 629 3457040 
628 3454150 2 631 3452230 
3 625 3453180 
55 
1 632 3455214 
631 3454216 2 630 3452103 
3 630 3455330 
60 
1 628 3455560 
627 3453950 2 629 3450350 
3 625 3455940 
80 
1 630 3454190 
629 3455363 2 632 3455020 
3 626 3456880 
100 
1 628 3456460 
629 3455273 2 626 3453220 
3 632 3456140 
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Table 4A: AdSSPEGOMe:𝛽CD-C12 fluorescence measurements with varying concentration of 
amphiphile and 0.156 𝜇𝑔/𝑚𝐿 nile red 
[Amphiphile] 
(𝝁𝑴) Trial # 𝝀𝒆𝒎	𝒎𝒂𝒙 (nm) Intensity (CPS) Avg 𝝀𝒆𝒎	𝒎𝒂𝒙 (nm) Avg Intensity (CPS) 
10 
1 602 3408420 
602 3388790 2 601 3427360 
3 602 3330590 
15 
1 605 3639430 
601 3630130 2 600 3655010 
3 598 3595950 
20 
1 614 3991630 
614 3947913 2 617 3921670 
3 612 3930440 
25 
1 604 4021960 
607 4043417 2 608 4070560 
3 608 4037730 
30 
1 602 4175370 
603 4136443 2 600 4129650 
3 607 4104310 
35 
1 612 4218940 
614 4213830 2 616 4212240 
3 615 4210310 
40 
1 617 4236910 
615 4240427 2 614 4240600 
3 615 4243770 
60 
1 646 4238920 
644 4243220 2 644 4245160 
3 643 4245580 
80 
1 655 4247980 
655 4242870 2 655 4244910 
3 655 4235720 
100 
1 649 4240510 
648 4241117 2 647 4240730 
3 647 4242110 
 
 
Table 5A: AdSSPEGOMe:𝛽CD-C14 fluorescence measurements with varying concentration of 
amphiphile and 0.156 𝜇𝑔/𝑚𝐿 nile red 
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[Amphiphile] 
(𝝁𝑴) Trial # 𝝀𝒆𝒎	𝒎𝒂𝒙 (nm) Intensity (CPS) Avg 𝝀𝒆𝒎	𝒎𝒂𝒙 (nm) Avg Intensity (CPS) 
10 
1 604 2542740 
605 2583310 2 605 2564350 
3 606 2642840 
15 
1 607 2839610 
607 2847270 2 609 2850090 
3 605 2852110 
20 
1 608 3178680 
610 3152350 2 611 3168110 
3 611 3110260 
25 
1 614 3504140 
612 3557280 2 612 3637400 
3 611 3530300 
30 
1 611 4095710 
611 4067563 2 612 4021950 
3 611 4085030 
35 
1 610 4248320 
612 4248627 2 614 4243780 
3 611 4253780 
40 
1 615 4246680 
616 4248283 2 618 4248340 
3 616 4249830 
60 
1 640 4245970 
640 4245567 2 640 4247670 
3 641 4243060 
80 
1 655 4243540 
653 4244843 2 653 4247530 
3 652 4243460 
100 
1 650 4246240 
650 4245027 2 652 4246670 
3 648 4242170 
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Table 6A: Particle size measurements for inclusion complexes and host and guest on their own 
prepared by probe sonication vesicle isolation method 
 
Sample Ratio (host:guest) 
Time 
(days) 
Hydrodynamic 
Radius (nm) %Intensity %PD 
AdSSPEG1000 0 to 1 
0 1.522 2.1 40.6 95.123 97.9 44.2 
1 0.706 2.1 18.6 11.236 2.2 15.7 
AdSSPEG1000OMe 0 to 1 
0 6.28 0.9 10.8 106.642 99.1 106.8 
1 
6.03 5.1 8.8 
42.443 60.9 17.6 
187.776 34 16.8 
bCD-C12 1 to 0 
0 
7.097 2.8 11.9 
88.23 76 36.3 
1189.18 18.1 56.2 
19018.2 3.1 43.8 
1 
6.827 1.6 11.5 
93.824 54.3 11.7 
503.546 44 12.1 
bCD-C14 1 to 0 
0 
3.912 0.7 0 
9.791 0.7 7.9 
73.922 64.7 21.8 
384.427 33.9 16.3 
1 3.689 1 9.9 161.629 93.5 85.2 
AdSSPEG1000/bCD-C12 1 to 1 
0 
1.704 2.3 12.8 
107.131 90.4 58.9 
934.781 7.3 30.5 
1 2.239 1.6 19.7 113.813 98.4 66.1 
AdSSPEG1000/bCD-C14 1 to 1 
0 
1.648 1.8 13.8 
97.53 71.7 52.4 
518.176 26.5 43.9 
1 
2.747 1.4 11.9 
33.446 9 17.3 
112.225 81.7 29.1 
1333.97 7.9 20.5 
AdSSPEg1000OMe/bCD-C12 1 to 1 
0 
6.291 4.2 0 
128.431 92.6 98.3 
14920.5 3.2 57.1 
1 
3.247 1.9 11.8 
39.506 34.5 37.2 
222.854 63.7 47.5 
AdSSPEG1000OME/bCD- C14 1 to 1 
0 
5.059 2 6.9 
94.234 92.3 23.6 
535.093 5.7 19 
1 6.1 1.4 7.9 119.979 98.6 18.5 
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Table 7A: Particle size measurements for inclusion complexes and host and guest on their own 
prepared by extrusion vesicle isolation method 
Sample Ratio (host:guest) 
Time 
(days) 
Hydrodynamic 
Radius (nm) %Intensity %PD 
AdSSPEG1000 0 to 1 
0 
0.569 0.2 19.4 
5.383 0.7 15.6 
70.162 99.2 34.4 
1 
5.472 1 11.8 
67.59 86.9 27.1 
296.919 12.1 16.8 
AdSSPEG1000OMe 0 to 1 
0 
3.458 2.5 11.9 
20.406 18.8 16.6 
71.553 78.7 19.7 
1 
11.236 11.8 11.9 
59.84 88.2 24 
bCD-C12 1 to 0 
0 
4.29 0.7 11.7 
67.057 99.3 39.7 
1 
1.724 0.1 11.8 
8.475 2 10.4 
62.095 94.9 12.6 
430.904 2.9 9.3 
bCD-C14 1 to 0 
0 
1.397 0.1 11 
98.248 96.2 69 
817.548 3.6 29.1 
1 
1.929 1.6 3.8 
88.27 91 42.6 
1300.87 7.4 70.9 
AdSSPEG1000:bCD-C12 1 to 1 
0 
5.026 1.3 5.2 
64.357 98.7 32.3 
1 
3.5 12 11.8 
95.98 88 11.9 
AdSSPEG1000:bCD-C14 1 to 1 
0 
1.016 0.7 11.4 
13.692 4.9 15.5 
64.336 94.5 28.2 
1 
1.349 0.7 12.7 
69.188 99.3 48.5 
AdSSPEg1000OMe:bCD-C12 1 to 1 
0 
9.19 6.9 11.5 
64.121 93.1 32.4 
1 
7.803 6.7 6.6 
61.905 93.3 16.8 
AdSSPEG1000OMe:bCD- C14 1 to 1 
0 
5.814 6.6 11 
48.21 93.4 21.2 
1 
6.515 7.3 8.8 
51.361 92.7 22.2 
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Figure 6A: Initial lysing of AdSSPEGOMe:βCD-C14 inclusion complex measured via fluorescence 
spectroscopy.. When lysed with 250 µL 10% Triton X-100 there is a large increase in fluorescence 
intensity which indicates vesicles formed with encapsulated CF 
Figure 7A: Initial lysing of AdSSPEG:βCD-C14 inclusion complex measured via fluorescence 
spectroscopy. When lysed with 250 µL 10% Triton X-100 there is a large increase in fluorescence 
intensity which indicates vesicles formed with encapsulated CF 
 
*Note – AdSSPEGOMe:	βCD-C12 initial lysing measurements can be found on page 106 
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Figure 8A: Initial lysing of AdSSPEG:βCD-C12 inclusion complex measured via fluorescence 
spectroscopy. When lysed with 250 µL 10% Triton X-100 there is a large increase in fluorescence 
intensity which indicates vesicles formed with encapsulated CF 
 
Figure 9A: Initial lysing of AdSSPEGOMe guest measured via fluorescence spectroscopy. When 
lysed with 250 µL 10% Triton X-100 there is a small increase in fluorescence intensity which 
indicates vesicles did not form 
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Figure 10A: Initial lysing of AdSSPEG guest measured via fluorescence spectroscopy. When lysed 
with 250 µL 10% Triton X-100 there is a small increase in fluorescence intensity which indicates 
vesicles did not form 
 
Figure 11A: Initial lysing of βCD-C12  host measured via fluorescence spectroscopy. When lysed 
with 250 µL 10% Triton X-100 there is a small increase in fluorescence intensity which indicates 
vesicles did not form 
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Figure 12A: Initial lysing of βCD-C14  host measured via fluorescence spectroscopy. When lysed 
with 250 µL 10% Triton X-100 there is a small increase in fluorescence intensity which indicates 
vesicles did not form 
 
Figure 13A: 1 week lysing of AdSSPEGOMe:βCD-C14 inclusion complex measured via 
fluorescence spectroscopy is consistent with initial measurements 
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Figure 14A: 1 week lysing of AdSSPEGOMe:βCD-C12 inclusion complex measured via 
fluorescence spectroscopy is consistent with initial measurements 
 
Figure 15A: 1 week lysing of AdSSPEG:βCD-C12 inclusion complex measured via fluorescence 
spectroscopy is consistent with initial measurements 
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Figure 16A: 1 week lysing of AdSSPEG:βCD-C14 inclusion complex measured via fluorescence 
spectroscopy is consistent with initial measurements 
 
Figure 17A: 1 week lysing of AdSSPEGOMe guest measured via fluorescence spectroscopy is 
consistent with initial measurements 
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Figure 18A: 1 week lysing of AdSSPEG guest measured via fluorescence spectroscopy is consistent 
with initial measurements 
Figure 19A: 1 week lysing of βCD-C12 host measured via fluorescence spectroscopy is consistent 
with initial measurements 
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Figure 20A: 1 week lysing of βCD-C14  host measured via fluorescence spectroscopy is consistent 
with initial measurements 
 
Figure 21A: 2 week lysing of AdSSPEGOMe:βCD-C14  inclusion complex measured via 
fluorescence spectroscopy. When lysed with 250 µL 10% Triton X-100 there is a small increase in 
fluorescence intensity which indicates vesicles have degraded 
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Figure 22A: 2 week lysing of AdSSPEGOMe:βCD-C12  inclusion complex measured via 
fluorescence spectroscopy. When lysed with 250 µL 10% Triton X-100 there is a small increase in 
fluorescence intensity which indicates vesicles have degraded  
Figure 23A: 2 week lysing of AdSSPEG:βCD-C12  inclusion complex measured via fluorescence 
spectroscopy. When lysed with 250 µL 10% Triton X-100 there is a small increase in fluorescence 
intensity which indicates vesicles have degraded 
 
 
 
30000
80000
130000
180000
230000
0 10 20 30 40 50 60 70 80 90
Fl
uo
re
sc
en
ce
 In
te
ns
ity
 (C
PS
)
Time (s)
AdSSPEGOMe1000:𝛽CD-C12 (1:1)
38000
58000
78000
98000
0 10 20 30 40 50 60 70 80 90
Fl
uo
re
sc
en
ce
 In
te
ns
ity
 (C
PS
)
Time (s)
AdSSPEG1000:𝛽CD-C12 (1:1)
10% TritonX-100 added 
10% TritonX-100 added 
159 
 
Figure 24A: 2 week lysing of AdSSPEG:βCD-C14  inclusion complex measured via fluorescence 
spectroscopy. When lysed with 250 µL 10% Triton X-100 there is a small increase in fluorescence 
intensity which indicates vesicles have degraded 
Figure 25A: 2 week lysing of AdSSPEG guest measured via fluorescence spectroscopy is consistent 
with initial measurements 
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Figure 26A: 2 week lysing of AdSSPEGOMe guest measured via fluorescence spectroscopy is 
consistent with initial measurements 
 
Figure 27A: 2 week lysing of βCD-C12  host measured via fluorescence spectroscopy is consistent 
with initial measurements 
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Figure 28A: 2 week lysing of βCD-C14  host measured via fluorescence spectroscopy is consistent 
with initial measurements 
 
 
 
 
Table 8A: Particle size measurements of vesicles treated with 12 mM GSH to mimic intracellular 
environments  
Sample Ratio (host:guest) 
Time Since GSH 
Added 
Hydrodynamic 
Radius (nm) %Intensity %PD 
AdSSPEG1000:𝛃CD-C12 1 to 1 before 5.026 1.3 5.2 64.357 98.7 32.3 
overnight 0.589 16 55.2 1159.24 84 330.7 
AdSSPEG1000:𝛃CD-C14 1 to 1 before 1.016 0.7 11.4 13.692 4.9 15.5 64.336 94.5 28.2 
overnight 0.618 63.8 41.4 153.649 36.2 67 
AdSSPEg1000OMe:𝛃CD-C12 1 to 1 before 
9.19 6.9 11.5 
64.121 93.1 32.4 
overnight 
2.432 0.7 0 
22.242 24.8 11.3 
77.074 69.8 18.7 
495.931 4.7 8.1 
AdSSPEG1000OMe:𝛃CD- C14 1 to 1 before 5.814 6.6 11 48.21 93.4 21.2 
overnight 
0.604 5.3 36.6 
56.458 92.6 87 
905.557 2.2 34.3 
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 Table 9A: Particle size measurements of vesicles treated with 20 𝜇M GSH to mimic extracellular 
environments 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample Ratio (host:guest) 
Time Since GSH 
Added 
Hydrodynamic 
Radius (nm) %Intensity %PD 
AdSSPEG1000:	𝛃CD-C12 1 to 1 before 5.026 1.3 5.2 64.357 98.7 32.3 
overnight 
0.512 0.9 21.7 
95.004 99.1 57.3 
AdSSPEG1000:	𝛃CD-C14 1 to 1 before 
1.016 0.7 11.4 
13.692 4.9 15.5 
64.336 94.5 28.2 
overnight 
1.902 9.4 44.3 
59.337 90.6 38.4 
AdSSPEG1000OMe:	𝛃CD-
C12 1 to 1 
before 
9.19 6.9 11.5 
64.121 93.1 32.4 
overnight 
4.563 1.3 11.2 
62.883 98.7 46.3 
AdSSPEG1000OMe:	𝛃CD- 
C14 1 to 1 
before 
5.814 6.6 11 
48.21 93.4 21.2 
overnight 
6.09 2.4 20.4 
57.139 97.6 46.3 
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Table 10A: Particle size measurements of vesicles and PEGdiSH crosslinker [7e] with a molecular 
weight of 10000 g/mol 
 
Sample Ratio (host:guest) 
Mol 
Ratio 
SH/SS 
SH % 
wt 
Time Since 
Crosslinker 
Added 
Hydrodynamic 
Radius (nm) %Intensity %PD 
AdSSPEG1000:𝛃CD-C12 1 to 1 1 to 1 20 before 
5.026 1.3 5.2 
64.357 98.7 32.3 
overnight 
7.43 3.2 10.6 
35.243 9.3 16.2 
99.55 87.4 25.5 
AdSSPEG1000:𝛃CD-C14 1 to 1 1 to 1 20 before 
1.016 0.7 11.4 
13.692 4.9 15.5 
64.336 94.5 28.2 
overnight 
9.56 8 9.8 
72.737 92 19 
AdSSPEg1000OMe:𝛃CD-
C12 1 to 1 1 to 1 20 
before 
9.19 6.9 11.5 
64.121 93.1 32.4 
overnight 
3.496 1.7 11.8 
107.038 98.3 9.7 
AdSSPEG1000OMe:𝛃CD- 
C14 1 to 1 1 to 1 20 
before 
5.814 6.6 11 
48.21 93.4 21.2 
overnight 
1.487 4.6 5.8 
144.648 85 16.2 
3304.26 10.4 25.4 
